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In addition to the endocrine regulatory functions on female reproductive system, 
scientists are interested in studying other physiological effects of oestrogen. One of the 
new oestrogenic effects discovered was related to inflammatory processes. Interstitial 
cystitis, a urinary bladder inflammatory disease, characterised by pelvic and intense 
bladder pain, urinary frequency and pain with urination, is believed to be a condition of 
women. The intensity of pain will change according to menstrual cycle and age and is 
believed to be related to the level of oestrogen and mast cell activation. 
In our studies, we investigated the relationship between oestrogens and mast cells. 
Sprague Dawley rats of both genders as well as ovariectomized female rats were 
employed. The ovariectomized animals served as a model for postmenopausal stage of 
rats. The release of histamine from peritoneal mast cells was used as an indicator of mast 
cell activation. The physiological oestrogen, 17/5-estradiol, and selective oestrogen 
receptor modulators, tamoxifen and raloxifene were used to study oestrogenic effects on 
mast cells activation by secretagogues including anti-IgE, compound 48/80 and 
substance P. In order to confirm non-genomic pathway through cell surface oestrogen 
receptors, the effects of membrane impermeable BSA-conjugated estradiol, 
actinomycin-D (transcription blocker) and cycloheximide (translation blocker) were 
compared. To further elucidate the involvement of oestrogen receptors in the regulation 
of mast cells activation, specific oestrogen receptors agonists (e.g. DPN and PPT) and 
antagonists (e.g. ICI 182780 and MPP hydrochloride) were used. The specificity of 
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drugs allows us to determine which oestrogen receptors subtypes were involved. The 
mRNA expression of oestrogen receptor subtypes on rat peritoneal mast cells (RPMCs) 
was verified by reverse-transcriptase PCR method. 
Our results suggested that 17/5-estradiol, tamoxifen, raloxifene, PPT, DPN and BSA-
conjugated estradiol alone can initiate histamine release (5-10%) from RPMCs. 
Moreover, when mast cells secretagogues anti-IgE, compound 48/80 or substance P was 
added to mast cells preincubated with oestrogenic agents to 10 minutes, a suppression of 
histamine release without dose-dependent trend was observed. In the anti-IgE induced 
histamine release assay from male RPMCs, the highest percentage of inhibition by 17p-
estradiol, tamoxifen, raloxifene, PPT and DPN at their corresponding concentration were 
44.8 士 6.30/0 (lO'^M), 42.3 士 10.8o/o (IQ-^M), 69.5 士 18.1o/o (IQ-^M), 42.7 士 19.6o/o (IQ-^M) 
and 40.2 士 8.7o/o (lO'^M) respectively. Raloxifene however enhance histamine release in 
certain dose range (10'^ - lO'^M). The results obtained were similar to compound 48/80 
and substance P stimulated ones, general inhibitory effect was observed. We have 
conducted three different incubation time points (0, 10 and 30 minutes) of drugs together 
with RPMCs. We found out that the above results can be observed within first 10 
minutes. These rapid actions of oestrogens suggest the involvement of membrane 
surface oestrogen receptors and was confirmed by the observations that the membrane 
impermeable BSA-conjugated estradiol was capable of producing similar level of 
inhibition in all four groups of tested animals. To further support the participation of the 
non-genomic pathway, transcription and translation blockers were added subsequently to 
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the oestrogenic agents pre-incubated RPMCs. The inhibitory results by oestrogenic 
agents on secretagogues induced histamine release were not affected. 
General oestrogen receptor antagonist (ICI 182780) and specific oestrogen receptor a 
antagonist (MPP dihydrochloride) showed reversal effects on inhibited anti-IgE induced 
histamine release of oestrogenic agents from male RPMCs. The enhancing effect 
induced by raloxifene at lO'^M was also suppressed by MPP dihydrochloride. These 
suggested that the inhibitory and enhancing effect of histamine release work through 
oestrogen receptor a subtype. However, the oestrogenic effects on stimulating low level 
histamine release from non-stimulated RPMCs were not masked by the addition of 
antagonists. The results, all together, suggested that the oestrogenic effects on RPMCs 
act via two different pathways: oestrogen receptor dependent inhibition and oestrogen 
receptor independent stimulation. To further confirm the existence of oestrogen receptor 
a on RPMCs, mRNA expression of oestrogen subtypes were checked and oestrogen 
receptor a was expressed. 
To summarize, oestrogenic agents were able to induce low level histamine release from 
RPMCs. At the same time, they were also capable to inhibit secretagogues induced 
histamine release from RPMCs. However, further detail studies are required to elucidate 
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Chapter 1 ： Introduction 
1. Introduction 
1.1 Mast Cell 
Mast cell was first identified by a medical student, Paul Ehrlich, 100 years ago. He 
demonstrated that aniline dyes were able to stain certain granular cells of connective 
tissue. These cells with numerous stained granules of varying size that filled the 
unstained protoplasm appeared to be well-fed, therefore Ehrlich named them the 
"mastzellen", or in English “mast cell”，which means well-fed cells. Although he 
observed that the mast cells were generally situated in connective tissues near blood 
vessels, nerves, glandular ducts as well as in inflammatory and neoplastic foci, the 
physiological functions related to the mast cells remained unclear (Stassen et al., 2002; 
Vyas et al). 
Portier and Richet first described the phenomenon of anaphylaxis in 1902. They defined 
two basic principles for anaphylaxis: initial inoculation of proteins can induce sensitivity 
development and an incubation period between the initial inoculation and the 
development of sensitivity is required. Subsequently, it was shown that serum obtained 
from animals initially immunized contained a circulating factor which was capable of 
transferring this hypersensitivity to normal animals (Metcalfe et al” 1981). In the late 
60s, the factor was finally recognized as the immunoglobulin E (IgE). Shortly after the 
recognition of IgE, numbers of unique functions of mast cells were clarified. It is now 
1 
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well known that mast cell can discharge chemical mediators upon exposure of 
appropriate antigens to its unique cell surface IgE, which reveals a correlation between 
IgE, mast cells and anaphylaxis. 
1.1.1 Origin of Mast Cell 
It is now clear that mast cell precursors are derived from multipotent stem cells in bone 
marrow. By bone marrow transplantation, mice which were deficient in mast cells could 
result in a dramatic increase in the content of mast cells in skin, stomach, and mesentery 
after 3 to 4 months (Kitamura, 1989). The mast cell progenitors complete their 
differentiation into specific mast cell subtypes at the tissue sites according to the growth 
factors, cytokines and other factors present in the micro environment. Human bone 
marrow mononuclear cells and CD34+ stem cells when cultured with interleukin (IL)-3 
and stem cell factor (SCF) respectively, gave rise to mast cells (Kitamura et aL, 1993). 
Studies even suggested that factors influencing mast cell development may exert 
different effects depending on the state of mast cell maturation when they come in 
contact with the cells (Hu et al” 1996; Kitamura et al., 1993; Nilsson et al.’ 1994). Mast 
cell maturation was shown to be either stimulated or inhibited by interleukin-1 (IL-1), 
interleukin-4 (IL-4) and interferon gamma (IFN- 7) . For instance, IL-4 inhibits the 
expression of c-kit and tryptase by human liver mast cell progenitors (Nilsson et al., 
1994) while it stimulates mast cell development when combined with IFN- 7 (Rottem et 
al., 1995). 
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1,1.2 Heterogeneity of Mast Cell 
The concept of mast cell heterogeneity was first raised by Enerback in the mid 1960's 
through series of detailed morphological and histochemical studies on the 
gastrointestinal tract of rats (Forsythe et al., 2000). He noted that mast cells found in the 
deeper layers of the intestinal wall or submucosa were very similar to those found in 
connective tissues while those found in mucosa displayed different properties. They 
were much smaller and more variable in shapes when compared with the mast cells 
located in connective tissue sites. They have fewer granules and contain lower levels of 
histamine (Forsythe et al., 2000). The two rat mast cell subtypes were then classified as 
mucosal mast cell (MMC) and connective tissue mast cell (CTMC) according to their 
anatomical locations (Forsythe et al., 2000). The two types of rat mast cells can also be 
classified according to different proteoglycan content found within secretory granules: 
heparin being predominant in CTMCs whereas chondroitin sulphates being predominant 
in MMCs (Stevens et al., 1985). Functionally, different responses are elicited by 
different secretagogues in the two types of rat mast cells. While both respond to 
immunological stimulation by anti-IgE and non-immunological stimulation by calcium 
ionophores, only CTMCs can be stimulated non-immunologically by basic 
secretagogues such as compound 48/80, substance P, bradykinin and somatostatin 
(Kitamura, 1989). 
However in human, mast cell heterogeneity cannot conveniently be classified as 
'mucosal' or 'connective tissue’ types according to their environmental locations. 
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Instead human mast cells are distinguished into two populations by means of their 
different neutral protease content. The population that contains measurable amounts of 
both chymase and tryptase is known as MCTC and another population which contains 
only tryptase is named MCT (Irani et al., 1986; Sperr et al,, 1994). The MCjc cells are 
predominant in skin and intestinal submucosa whereas the MCT cells are predominant in 
lung and intestinal lamina propria. 
As stated, mast cells differentiate into respective subtypes according to the specific 
tissue micro environment. The complex microenvironment is actually governed by a 
variety of cells which are in close contact with mast cells. These cells often synthesize 
and secrete diverse growth factors, histamine release factors, cytokines and chemokines, 
all of which can determine mast cell phenotype. Functional heterogeneity of the two 
types of human mast cells especially their response to stimuli is observed (Forsythe et al., 
2000). Studies revealed that significant amounts of histamine was released from human 
skin mast cells when challenged by compound 48/80, while mast cells from colonic and 
lung are unresponsive (Damazo et al., 2001). Substance P, another mast cell 
secretagogue, which is able to cause histamine release from human skin and 
bronchoalveolar lavage (BAL) again were ineffective against mast cells from human 
lung (Forsythe et al., 2000). 
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1.1.3 Activation of Mast Cells 
The classical activation of mast cells involves IgE-mediated stimulation through the 
high-affinity cell surface receptor (FceRI). The FceRI are expressed on the surface of 
mast cells in the form of a tetrameric complex. It is composed of a IgE-binding a chain, 
a membrane-tetraspanning jS chain and two disulphide-linked homodimeric 7 chains. 
Both l3 and 7 chains comprised of an immunoreceptor tyrosine based activator motif 
(ITAM) which is essential for amplifying and completing signals respectively (Rivera et 
a/., 2006). 
1.1.3.1 IgE-dependent Mast cell Activation 
Immunoglobulin E-dependent mast cell activation is a major triggering mechanism for 
both acute and chronic allergic reactions. This temperature-dependent activation of mast 
cells can be completed within 1 to 2 minutes and the presence of divalent cations (e.g. 
Ca2+) is often required (Metcalfe et al., 1981). Antigen specific IgE molecules are 
produced by plasma cells subsequent to the initial exposure to the antigen. The antigen 
specific IgE molecules then bind to the FceRI on mast cell surface. Further exposure of 
antigens to these sensitized mast cells facilitates crosslinking of cell surface IgE 
molecules and subsequently aggregate the FceRL The crosslinking of FceRI leads to the 
activation of mast cells. In fig 1.1, the IgE-dependent mast cell activation pathway was 
shown and will be described in detail in the following paragraphs. Lyn, a Src family 
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protein tyrosine kinase (PTK), which is originally associated to the P chain is activated 
and subsequently phosphorylates tyrosine residues in the ITAMs in the 3 and 7 chains. 
The phosphorylated ITAMs then provide high-affinity docking sites and recruit more 
PTK including Lyn, Syk and Fyn, for coordinating further downstream signaling 
pathways required for the release of various pro-inflammatory mediators. 
A transmembrane adaptor molecule, linker for the activation of T cells (LAT), is further 
phosphorylated by Lyn and Syk subsequently. There are four terminal tyrosine residues 
in LAT (Y132, Y171，Y191 and Y226) which are important for LAT to regulate 
signaling for mast cells degranulation (Saitoh et al., 2003). Studies demonstrated LAT 
deficiency in mast cells results in loss of signal transduction and eventually block mast 
cell degranulation. Secretion of two mediators, serotonin and jS-hexosaminidase, was 
markedly impaired in LAT deficiency bone marrow-derived mast cells (Saitoh et al., 
2000). The phosphorylation of LAT at these tyrosine residues further recruits more types 
of molecules: including cytosolic adaptor molecules, such as growth-factor-receptor-
bound-protein 2 (GRB2), GRB2-related adaptor protein (GADS), SH2-domain-
containing transforming protein C (SHC) and SH2-domain-containing leukocyte protein 
of 76 kDa (SLP76); guanine-nucleotide- exchange factors and adaptors molecules, such 
as son of sevenless homologue (SOS) and the ‘one F' proto-oncogene Vav protein; and 
signaling enzymes, such as phospholipase C71 ( P L C 7 1 ) for later cytokines production 
and mast cell degranulation (Gilfillan et al., 2006). 
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The production of cytokines and eicosanoids are also activated following the RAS-RAF-
mitogen-activated protein kinase (MAPK) pathway (Kopec et al., 2006). The MAPKs 
are a group of protein kinases, mediating signals from cell surface to nuclear. SOS and 
VAV which are recruited by phosphorylated LAT further phosphorylate RAS, from its 
inactive state (GDP bound) to active state (GTP bound). The active RAS binds directly 
to a serine-threonine kinase, RAF, forming a transient membrane-anchoring signal. The 
active RAF then phosphorylates tyrosine residues on the MAPKs: the extracellular-
signal-regulated kinase 1 (ERKl) and extracellular-signal-regulated kinase 2 (ERK2). 
The phosphorylated MAPKs then activate the transcriptional factors, including activator 
protein 1 (API) components (FOS and JUN), nuclear factor of activated T cells (NFAT) 
and nuclear factor-/cB (NF-/cB), leading to the cytokines generation (Gilfillan et al, 
2006). NF-fcB is a master transcription factor which regulates most of the pro-
inflammatory cytokines, of which TNF-a and IL-6 expression in response to FceRI 
activation is strictly dependent on NF-/cB (Klemm et al., 2006). At the same time, PLA2 
is activated and lipid mediators (e.g. prostaglandins and leukotrienes) are formed. 
On the other hand, P L C 7 1 recruited through the activation of LAT catalyses the 
hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) in the plasma membrane, 
generating inositol-1,4,5-triphosphate (EP3) and diacylglycerol (DAG), and thus induce 
mobilization of cytosolic calcium and activation of protein kinase C (PKC) respectively. 
Both movement of calcium and activation of PKC induce downstream degranulation 
processes and promote activation of various molecular pathway transcription factors 
which results in pro-inflammatory cytokines and growth factors synthesis (Gilfillan et 
7 
Chapter 1 ： Introduction 
al., 2006). The importance of calcium on mast cells degranulation will be discussed later 
in this chapter. The above activation pathways described are Lyn kinase dependent since 
Lyn-deficient bone marrow-derived mast cells (BMMCs) were shown to have impaired 
tyrosine phosphorylation and calcium mobilization ability. 
Further studies suggested that degranulation of Lyn-deficient mast cells was still 
massive even though the FceRI phosphorylation was reduced (Parravicini et al., 2002) 
and these results suggested that an alternative Lyn-independent pathway is presence. 
Fyn-dependent signaling pathway is believed to be an alternative Lyn-independent 
pathway (Parravicini et al., 2002). Fyn belongs to the Src family of PTK and is recruited 
similarly as Lyn kinase. By activating Fyn, GRB2-associated binder protein 2 (GAB2) 
will then be phosphorylated rapidly and form a signaling complex containing tyrosine 
phosphatase and phophatidylinositol 3-OH kinase (PI3K). The phosphorylated PI3K 
then results in the production of phosphatidylinositol-3,4,5-triphosphate (PIP3), which is 
important in controlling calcium movement. PIP3 further activates PI3K-dependent 
kinase (PDKl) and lastly protein kinase Akt is activated. Akt regulates several 
transcription factors activities, such as NF-zcB, NFAT and AP-1 which are important for 
the expression of cytokines released during degranulation. 
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Figure 1.1 Simplified scheme of FceRI signaling events in IgE-dependent mast cell 
activation. Aggregation of FceRI induce phosphorylation of LAT, which then recruits 
more types of molecules including P L C 7 I , GADS, SLP76, SOS, GRB and SHC. The 
recruitment of molecules further proceeds to downstream pathways which lead to mast 
cell degranulation and cytokines production. (Modified from (Gilfillan et al., 2006; 
Parravicini et al., 2002) 
9 
Chapter 1 ： Introduction 
1.1.3.2 IgE-independent Mast Cell Activation 
Besides activating the mast cells through IgE-dependent pathway, there are several 
methods in initiating mast cells effector functions. It has been well documented that 
high-affinity receptor for monomelic IgG (FC7RI) is expressed on mast cells surface. It 
comprises a single IgG-binding a chain and a 7 homodimer, which is also expressed in 
FceRL Once IgG molecules bind to the receptors, the receptors are crosslinked and the 
ITAMs present on the 7 chains are phosphorylated and lastly activate the Syk 
phosphorylation (Kopec et al., 2006). IgG pathway is very much similar to the IgE 
pathway, moreover PI3K pathway is more preferable than the other pathways and higher 
level of proinflammatory cytokines e.g. IL-1, IL-5, IL-6 and TNF-o: are detected in 
response to FC7RI than FceRI activation (Kopec et al., 2006). 
Direct activation of pertussis toxin (PTX)-sensitive G-proteins is believed to be one of 
the pathways in activating mast cell degranulation (Aridor et al., 1990; Mousli et al., 
1990); (Stassen et al., 2002). However the detailed mechanism is still not clear. 
Substance P, a type of tachykinin, was shown to induce a rapid increase in intracellular 
calcium which is independent of external calcium sources. This suggested that substance 
P may activate phospholipase C which stimulates phosphoinosital breakdown, forming 
PIP3 which controls and releases internal calcium and lead to exocytosis (Lorenz et al., 
1998). The amphiphilic arginine and lysine residues present at the N-terminus of 
substance P are essential for inducing mast cell secretion and it is expected that a deep 
insertion of substance P into the plasma membrane can translocate signals into the 
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cytoplasm and reach the G-proteins (Mousli et al., 1989). Compound 48/80, a mixed 
polymer of phenylethylamine cross-linked by formaldehyde, is another basic mast cell 
secretagogue which is capable of inducing release of mediators (e.g. histamine) from the 
mast cell. The mechanism of compound 48/80 induced mast cell activation is similar to 
that of substance P in which the phospholipase C is activated through a G-protein (Ferry 
et al., 2002). These mast cell activating peptides and basic secretagogues are believed to 
act through a receptor-independent effect. Unlike IgE-dependent activation, calcium in 
the media for completing the reaction is not necessary. 
Besides activating the G-protein directly to cause mast cell activation, alteration of 
intracellular calcium [Ca]i by calcium influx from extracellular media is another possible 
way. lonophore A23187 is used to induce mast cell activation. It is a lipid soluble 
carboxylic acid antibiotic which specifically forms complex with calcium and transports 
the ion across the cell membrane. The calcium influx increases [Ca]i which in turns 
leads to mast cell degranulation. Histamine release is induced by A23187 in a dose and 
temperature-dependent manner. The activation relies heavily on the concentration of 
extracellular calcium in buffer (Cochrane, et al., 1974; Johansen, 1978). 
Mast cells can also be activated by bacteria interactions and viral proteins. They play a 
key role in innate immune response against bacterial and viral infections. Bacterial 
infections initiate either classical or alternative pathways of the complement system. 
However, both pathways then join at the C3 activation step and proceed in common 
thereafter. Low molecular weight split products from C3, C4 and C5 activation, known 
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as C3a, C4a and C5a, are recognized as non-immunologic mast cell degranulation agents 
and anaphylatoxins (Stassen et al., 2002). Mast cell degranulation by these 
anaphylatoxins is temperature dependent, requires the presence of calcium and the time 
course required for rat mast cell degranulation requires 30 to 60 minutes (Metcalfe et al., 
1981). As a consequence of mast cells and bacteria interaction, it has been shown that 
both gram-positive and gram-negative bacteria can be phagocytosed and killed by the 
mast cells. Furthermore, after phagocytic uptake of the bacteria, mast cells are able to 
process bacterial antigens for MHC-class I-mediated presentation. 
1.1.3.3 Importance of Calcium 
Calcium is a universal secondary messenger and the increase of Ca^^ in the cytoplasm 
triggers biochemical reactions and physiological responses of cells. It is now clear that 
both increase in intracellular calcium concentration ([Ca ]i) and activation of calcium-
dependent pathways, such as calmodulin, protein kinase C and cytoskeletons are 
important for mast cell degranulation. In order to study the calcium effects on mast cells 
more effectively, calcium ionophores, which facilitate transport of Ca^^ across the 
plasma membrane, are used as valuable tools for the study. 
Generally the increase in subsequent to cross-linking of IgE receptors is 
characterized by two phases: an initial rapid increase that is followed by a sustained, 
elevated phase. The initial spike is mainly a result of Ca^^ release from intracellular 
stores. Various mast cell secretagogues (e.g. substance P, compound 48/80 and anti-IgE) 
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have been reported to induce mast cell degranulation in Ca-free buffer by inducing a rise 
in [Ca2+]i (Pearce et al., 1981; Penner et al., 1988; Zhang et al., 1995). The possible 
reason for this is by translocation of Ca^^ from internal pools to the cytoplasm. With the 
2+ 2+ help of the fluorescent dye Fura-2, a rapid release of Ca from intracellular Ca store 
was observed when mast cells were being challenged by compound 48/80 and substance 
P in Ca^^-free medium (Alfonso et al” 2000). Endoplasmic reticulum (ER) is believed to 
be the major internal Ca pool responsible for the [Ca ]i movement (Pearce et al., 1981; 
Tasaka, 1994). Studies indicated a direct relationship between the rate of 
phosphatidylinositol (PI) turnover and that of inositol (1,4,5) triphosphate (IP3) induced 
Ca2+ release from ER (Penner et al., 1988; Tasaka, 1994). According to the activation of 
phospholipase C pathway, PIP2 is hydrolyzed to generate IP3 which is the dominant 
second-messenger molecule for the release of intracellular Ca . 
The calcium influx from extracellular medium is suggested as the second phase of 
elevated and probably takes place through the opening of plasma membrane 
channels (Dar et al., 1992; Lee et al., 1995). One of such channels is associated with 
inositol (l,4,5)-triphosphate (IP3). The lowering of Ca^^ level in internal stores followed 
I • 
by an increase of IP3 opens Ca channels in the endoplasmic reticulum. However, the 
increase in Ca levels by emptying calcium store is not sufficient to cause mediators 
release from mast cells. Indeed, Ca^^ influx pathway is activated by Ca^^ amount in the 
internal store. As the concentrations of Ca^^ in stores fall, signal will be transduced from 
the stores to open Ca^^ channels in the plasma membrane. These Ca^^ channels are 
known as calcium-release activated calcium channels (CRAC) and this calcium selective 
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current is called ICRAC. The CRAC channels are non-voltage gated channels that have 
high selectivity for Ca^^ and are dependant on extracellular Ca^^ to maintain their 
activities (Chang, 2006). These channels are shown to be the predominant pathway of 
9+ 94-
Ca entry in mast cells, however other Ca influx pathways have been described and 
may also potentially modulate secretion. 
Other conductance pathways for calcium entry which are store-independent are 
represented by several cation channels. 50-pS cation channels were shown to have 
increased activity following stimulation with compound 48/80. However, these channels 
• , 2+ are not regulated by IP3. They are non-selective cation channels permeable to Ca and 
Mn . It is likely that a second messenger may take part in gating these channels as they 
are also activated by GTP-7-S or simply these channels may be directly gated by G 
proteins (Penner et al., 1988). Another non-selective channel with a large conductance 
of 250-pS and exhibits a high permeability to Ca^^ in RBL-2H3 mast cell line (Obukhov 
et al., 1995). The channels are stimulated with ATP and carbachol which lead to highly 
localized and transient increases in the cytosolic Ca concentration and initiates 
secretion. 
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1.1.3.4 Role of cyclic adenosine 3，，5'-monophosphate (cAMP) 
Changes in cAMP content of mast cells by a variety of pharmacologic stimuli were 
2+ 
studied in 1970s. During mast cell activation, the rise in Ca level inhibited mast cell 
adenylate cyclase and modestly stimulated mast cell phosphodiesterase. Both actions 
would tend to lower mast cell cAMP level (Sullivan et al., 1975a). Permeabilized rat 
peritoneal mast cells were used to show that histamine release induced by IP3 was 
inhibited dose-dependently by pretreatment with cAMP. Furthermore, cAMP also 
inhibited Ca^^ induced histamine release of rat mast cells (Tasaka, 1994). (3 -adrenergic 
agonists, phosphodiesterase inhibitors, prostaglandin E] (PGEi) and E2 (PGE2) which 
are able to increase cAMP content can all inhibit antigen induced histamine release from 
mast cells (Sullivan et al., 1975b). These findings suggested that elevations of cAMP 
can be correlated with inhibition of mediator release. 
Despite of the increased evidence for an inhibitory role of cAMP, the requirement of 
cAMP in signal transduction process for mast cell activation has also been suggested, as 
changes in levels of cAMP are observed following the activation of mast cells. A 
number of studies demonstrated a transient elevation of cAMP, within 5 to 20 seconds, 
following immunological activation of RPMCs using IgE and concanavalin A (Holgate 
et al., 1980; Leoutsakos et al” 1985). A stimulatory role for cAMP by providing 
electrical driving force for external calcium influx was suggested (Penner et al., 1988). 
These led to the suggestion that cAMP might play a role in pro-secretory signal in mast 
cells. However, when activating the mast cells by other secretagogues, such as 
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compound 48/80 and ionophore A23187，a rapid decrease in cAMP levels was detected 
(Leoutsakos et al., 1985). The results obtained clearly contradict the pro-secretory role 
of cAMP in mast cells, therefore, the role of cAMP as pro-stimulatory signal remains 
controversial. 
1.1.4 Mast Cells Mediators 
Upon mast cell activation, several inflammatory mediators responsible for 
pathophysiologic changes of allergic diseases are released (Barnes, 2002; Hart, 2001). 
Some of the mediators are preformed and stored in granules before mast cell activation 
while some mediators are formed and released as a consequence of the primary immune 
events. In human, inflammatory mediators include: histamine, neutral proteases, 
proteoglycans, leukotrienes, eosinophil chemotactic factor (ECF-A), prostaglandin D2 
(PGD2) , platelet activating factor (PAF), Hageman factor pathway enzymes and 
neutrophil chemotactic factor (NCF) are released upon mast cell activation (Ishizaka et 
al., 1987). 
Histamine is stored as a preformed mediator in granules of mast cells. It is synthesized 
from L-histidine by histidine decarboxylase found in mast cells. In human it can be 
metabolized by two major enzymatic pathways: either by N-methyltransferase and form 
N(3)-methylhistamine or histamine oxidase and form imidazole acetic acid. Histamine 
has several actions that are relevant to asthma and other allergic diseases. It exerts 
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bronchoconstrictor action mediated via histamine Hi-receptors but exerts bronchial 
vasodilation via histamine H2-receptors (Plaut et al). 
Mast cell protease is another preformed mediator which constitutes up to 30% of granule 
protein. Tryptase and chymase are the predominant proteases of human mast cells. They 
are able to cleave basement membrane proteins, neuropeptides and stimulate mucus 
secretion (Hart, 2001). It is well known that tryptase is able to cleave proteinase 
activated receptor-2 (PAR-2). PAR-2 belongs to a family of four G-protein coupled 
receptors (PAR-(l-4)). The cleavage of the extracellular part of PAR-2 leads to the 
exposure of a "tethered" tail which subsequently binds to receptor, inducing signaling 
events and receptor/ligand internalization. Several reports indicated that tryptase induces 
mitogen activated protein kinase (MAPK) pathway, induction of MEK and 
phosphatidylinosito 1 3-kinase as well as ERKl/2 (Hallgren et al., 2006). 
Leukotrienes and prostaglandins are synthesized from membrane phospholipids within 2 
minutes of mast cell activation. They include leukotriene C4 (LTC4) , leukotriene B4 
(LTB4) , P G D 2 and PAF. They are synthesized through the activation of MAPK pathway 
and play powerful roles as bronchoconstrictor and vasodilator agents (Hart, 2001). 
Phospholipase A2 is activated during inflammatory reactions and cleaves cell membrane 
phospholipids to release arachidonic acid. Arachidonic acid is then metabolized by 
either the lipoxygenase or cyclo-oxygenase pathways. The lipoxygenase pathway results 
in the formation of hydroxy! and hydroperoxy acids and leukotrienes while the cyclo-
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oxygenase pathway results in the formation of endoperoxides, which are then 
metabolized further to thromboxanes or prostaglandins (Plaut et al). 
Mast cell cytokines and chemokines are detected hours after mast cell activation. 
Cytokines include interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), 
interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-13(IL-13) 
and tumor necrosis factor-o: (TNF-a). Chemokines include neutrophil chemokines and 
nerve growth factor. All of them are important for recruitment of inflammatory 
leucocytes as part of both innate and acquired immunity (Hart, 2001). 
Preformed Mediators Histamine 
Proteoglycans 參 Heparin 
• Chondroitin Sulphate E 
Proteases 
參 Tryptase 參 Chymase 
Eosinophil Chemotratic Factor (ECF) 
Neutrophil Chemtractic Factor (NCF) 
Newly Synthesized Mediators Thromboxane A2 
Prostaglandins 
• P G D 2 
Leukotrienes 
參 I/TBQ，LTC4, L T D 4 
Platelet Activating Factor (PAF) 
Cytokines IL-3, IL-4, IL-5, IL-6, IL-8, 




Table 1.1 Different types of mast cell mediators release from activated human mast cells. 
Information was compiled from the following sources: 
(Metcalfe et al, 1981; Plaut et al\ Schwartz, 1994; Schwartz et al., 1993) 
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1.1.5 Physiological and Pathological Roles of Mast Cells 
Mast cells may play crucial roles on various disease states, including asthma, 
rheumatoid arthritis, atherosclerosis, interstitial cystitis, inflammatory bowel disease, 
ischemic heart disease and malignancy. In most cases (e.g. asthma, atherosclerosis and 
inflammatory bowel disease), numbers of activated mast cells positioned around the 
inflammatory sites are significantly increased. The mediators (e.g. histamine, P G D 2 ) 
released from mast cells have multiple effects including recruitment of other 
inflammatory cells as well as vascular dilatation (Krishnaswamy et al .,2006). 
Asthma is one of the mast cell activated allergic diseases correlated to activated mast 
cells. After exposure to allergen, allergic asthmatics will experience immediate, late or 
dual-phase allergic response. Immediate response takes place within minutes after 
exposure, followed by wheezing and cough. Mast cells play important roles in this stage. 
Increases in mast cell mediators including histamine (Casale et al” 1987), L T C 4 (Wenzel 
et al., 1989), P G D 2 (Liu et al., 1990; Miadonna et al., 1990) and tryptase (Wenzel et al., 
1988) were documented. Observable changes of blanching, hyperemia, mucosal 
swelling and then airway narrowing are observed. Four to eight hours following allergen 
exposure, a late response may occur. The symptom of airway obstruction is observed for 
12 to 24 hours but not much data related to mast cells in this stage were reported (Scott 
et al, 1993). 
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Mast cells also act as a neuroimmunoendocrine effector in interstitial cystitis (IC)，where 
activation of mast cells is exacerbated by neural, immune and endocrine components. 
Mast cells were shown to be activated by substance P released from nerve endings in IC 
patients' bladders. A number of studies had demonstrated increased numbers of mast 
cells in bladders of patients with IC. The possible explanation for that is the defective 
bladder epithelium in IC increases permeability and allows potential mast cell 
secretagogues to penetrate through the defective bladder lining and activate the mast 
cells. According to the electron microscopic examination of bladder mast cells from IC 
patients, fewer than 30% of the granules in mast cells remain intact, in contrast, over 
70% to 80% of normal bladder mast cells from control patients contained numerous 
homogenous, intact, electron-dense granules, indicating granules had been released from 
activated mast cells (Theoharides et al., 1998; Sant et al., 2007). Besides, this disease is 
found to be more abundant in female than male. Many female IC patients reported 
symptom exacerbations premenstrually or at the time of ovulation, during which the 
oestrogen levels remain high. This suggested a possible relationship between bladder 
mast cell activation and oestrogen levels. Furthermore, bladder mast cells in IC patients 
are shown to have increased expression of high-affinity estrogen receptors (Pang et al., 
1996). All of these suggested that female sex hormones may participate in the activation 
of bladder mast cells of this disease. 
Mast cells and their secreted products play a potential pathogenic role in the bone loss of 
osteoporosis. They are involved in the bone remodeling process affecting osteoclastic 
and osteoblastic recruitment and function. The exact mechanism by which mast cells 
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influence bone remodeling is still unknown. However, cytokines released from mast 
cells (e.g. IL-1, IL-3 and IL-6) are known to promote osteoclastic formation in a number 
of systems (Silberstein et al., 1991). Histamine, the major mast cell mediator, was 
shown to participate in the mediator network regulating osteoclastic resorption 
(Fouilloux et al., 2006). Two structurally different histamine H2 antagonists, cimetidine 
and famotidine, were found to protect trabecular bone in ovariectomized rats (Lesclous 
et al” 2004). 
The fall of circulating oestrogen level in post menopausal women was reported to be 
accompanied by an increased number of bone mast cells (Fallon et al, 1983). 
Furthermore, it was shown that oestrogen could inhibit cytokines release from human 
mast cells (Kim et al., 2001). Oestrogen is hence believed to produce a suppressive 
effect on mast cells. 
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1.2 Oestrogens 
Oestrogens belong to a group of steroid hormones that regulate growth, differentiations 
and functions in a wide range of target tissues in the human body. They are expressed in 
different level and can be found in both male and female. Three major naturally 
occurring oestrogens: oestrone, oestradiol and oestriol can be found, of which oestradiol 
is the most potent primary oestrogen. It is the most dominant oestrogen subtype in 
premenopausal women while oestrone is detected in a higher level at postmenopausal 
stage. The oestrogen level varies during the menstrual cycle and it plays important roles 
in several areas, such as promoting the formation of female secondary sex characteristics, 
protein synthesis as well as maintaining fluid balance. The oestrogen system is also 
involved in regulating the functions of the central nervous, skeletal and cardiovascular 
systems and this protects postmenopausal women from Alzheimer disease, osteoporosis 
and coronary heart diseases (Rollerova et al., 2000). 
Recently, the oestrogenic effects have been linked to the initiation, development as well 
as progression of most human breast cancers. Studies indicated that oestrogen signaling 
is required for the transformation of normal cells to malignant phenotype. The exact 
mechanism responsible for this transformation is still unclear but the critical role of 
oestrogen in the growth regulation of breast cancer is well established (Acconcia et al, 
2006). 
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1.2.1 Oestrogens and Inflammation 
Epidemiological pain studies have found that women are more likely to have a variety of 
persistent and temporary pains. In rat models, females often display higher pain scores in 
chronic and inflammatory pain models than males do. Ovarian hormones have been 
postulated to be responsible for these health disparities between sexes, of which 
oestrogen plays the most significant role in female. Recently, oestrogens have been 
related to several inflammatory diseases in cardiovascular (Maturana et al” 2007; 
Mendelsohn, 2000a; Rosano et al” 2006) and neuroimmune system (Canesi et al., 2006; 
Morale et al., 2006; Vegeto et al, 2006) providing either anti-inflammatory or pro-
inflammatory activities in different study models. 
1.2.1.1 Pro-inflammatory Effects of Oestrogen 
Interstitial cystitis (IC) is a painful bladder neuro-inflammatory disorder which occurs 
primarily in women. It includes symptoms of frequency, urgency, nocturia and burning 
pain which often worsen perimenstrually in most premenopausal women (Pang et al” 
1996). 
Women taking hormone replacement therapy (HRT) often have a higher incidence in 
developing asthma than those who are not taking (Bjorling et al., 2001). These 
epidemiological studies suggested that oestrogen may play a role in pro-inflammatory 
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action. IC patients were shown to have increased number of activated bladder mast cells, 
which express high affinity oestrogen receptors. These mast cells were located closely to 
the bladder nerves that were able to secrete the neuropeptide substance P as well as the 
neurotransmitter acetylcholine (ACh) (Pang et al., 1996; Theoharides et al., 1998). 
Several studies demonstrated that oestrogens have ability in augmenting mast cell 
activation (Cocchiara et al., 1992; Cocchiara et al., 1990; Vliagoftis et al., 1992). Mast 
cell mediators such as histamine and serotonin were released when challenged by 
substance P or the ACh analogue carbachol (Spanos et al., 1996). When supplemented 
with oestrogen, the release from mast cells increased. Similarly, releases of mast cell 
mediators induced by compound 48/80 and the calcium ionophore A23187 were also 
increased when challenged together with oestrogen (Vliagoftis et al., 1992). This 
suggested that oestrogens can enhance release of pro-inflammatory mediators. Study 
also implicated that several gene expressions were promoted by oestrogen in the uterine 
mast cells. Oestrogen augments mast cell pro-inflammatory molecules secretion before 
ovulation may help to explain the worsening of IC symptoms at perimenstrual stage. 
1.2.1.2 Anti-inflammatory Effects of Oestrogen 
Oestrogen exerts beneficial effects on cardiovascular system. Epidemiological studies 
indicated that cardiovascular diseases were less likely to happen in women than men 
(Stork et al., 2004). Observational studies suggested a 40-50% cardiovascular risk 
reduction in postmenopausal women using HRT. This led to hypothesis that sex 
hormones might be cardioprotective in women. The effects of oestrogens on 
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cardiovascular system have been studied and results showed that they can lower the 
levels of most of the inflammatory mediators (e.g. IL-1, TNF-a) which in turns decrease 
cardiovascular risk (Kim et al., 2001). The inhibition of inflammatory mediators release 
by oestrogen was later explained by the down regulation of gene expression of 
inflammatory mediators, of which, transcription factor NF-fcB was shown to be inhibited 
in human aorta endothelial cells (Chadwick et al., 2005). N F - K B is a redox sensitive 
transcription factor that regulates a multitude of inflammatory genes, including 
cytokines, chemokines, adhesion molecules, and acute phase proteins. Oestrogen was 
suggested to interfere with N F - k B activity through multiple mechanisms, including 
direct protein-protein interactions, inhibition of NF-fcB DNA binding or induction of I/cB 
expression (Chadwick et al., 2005; Ghisletti et al., 2005). Expression of another 
inflammatory mediator TNF-o: was also shown to be inhibited by oestrogen (An et al” 
1999; Cvoro et al, 2006). 
1.2.2 Oestrogen Signaling 
Similar to most steroid hormones, oestrogens have to interact with intracellular 
oestrogen receptor (ER) to exert actions physiologically. This classical genomic pathway 
plays a crucial role in developing normal functions of the female reproductive tract, 
secondary sex characteristics and in reproductive behavior. Moreover, evidences are 
accumulating within the last three decades, to suggest also the presence of non-genomic 
oestrogen signalings. 
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1.2.2.1 Classical Genomic Pathway 
The biological effects of oestrogens are mediated by two oestrogen receptor (ER) 
isoforms, ERo: and ERjS. Both of them are members of a large superfamily of nuclear 
receptors. ERa was first identified and isolated by Jensen and Jacobsen. In general, it is 
expressed in major female organs such as ovary, uterus, vagina，mammary glands and 
certain part of the nervous system, especially in hypothalamus (Hall et al., 2001). Until 
1996, another ER isoform was identified and later named as ER/3. ER/5 exhibits a more 
limited expression pattern and is primarily detected in ovary, spleen, lung, and thymus 
(Hall et al., 2001). Before the recognition of ERjS, ERo: was thought to be the sole 
receptor, it is now clear that ERa and ER/3 are encoded by different genes on different 
chromosomes and are located in different target tissues (Acconcia et al., 2006). 
ERs are activated through ligand-bound activity. Both share common biochemical 
anatomy and a high sequence of homology (Fig. 1.2). They consist of six modular 
domains: A/B, C, D, E and F which show five important functions: the N-terminal 
domain (A/B) is involved in both intermolecular and intramolecular interactions and in 
the activation of gene transcription; the DNA binding domain (DBD or C domain) 
allows receptor to dimerize and bind to specific oestrogen response element (ERE) on 
DNA through its 'zinc finger' structures; the hinge (D domain) plays a role in receptor 
dimerization and binding to chaperone heat shock proteins (Hsp); the relatively large C 
terminal (E domain) contains a ligand-binding domain (LBD) which determines the 
ligand binding specificity of ER and works synergistically with the A/B domain in the 
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regulation of gene transcription; and the F domain which is important in transcription 
activation and the repression activities of anti-oestrogens (Acconcia et al., 2006; 
Rollerova et al., 2000). 
The ERs have two transcription activation functions (AFs). One of which is a ligand-
independent AF-1 region, located within the N terminal (A/B domain); while the other 
one is a ligand-dependent AF-2 region located in the C terminal (E domain). Both AF-1 
and AF-2 regions interact with different coactivators and corepressors, triggering gene 
transcription separately and synergistically (Hall et al., 2001). The contribution of AF-1 
and AF-2 mediated gene transcription is dependent on cell phenotype. AF-1 functional 
activity is more prevalent in well differentiated cell while in undifferentiated cell, AF-2 
is responsible for the increased ER transcriptional activity. Both ERs share similar 
structure and functions, but they also show subtle and important functional differences, 
they undergo alternate splicing and give rise to variant proteins (Acconcia et al., 2006). 
The molecular mechanism of ERs is dependent on their cellular localization. The steroid 
hormone receptors ERs are mainly located in the cytoplasm as well as the nucleus of cell. 
In the absence of proper ligands, the ERs in the cytoplasm of target cells are associated 
with Hsps, which maintain an inactive status. Once the high affinity ligands bind to the 
LBD in ERs, the Hsps dissociate from the receptors and the ERs then undergo 
dimerization and translocate to the nucleus. In the nucleus, the dimerized ERs directly 
bind to the ERE in the promoter of related genes. The oestrogens-ER system then 
recruits more specific coactivators and corepressors for the subsequent gene 
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transcription (Acconcia et al., 2006). Coactivators and corepressors are proteins that 
interact with AF-2 activity of nuclear receptors in a hormone-dependent manner. They 
have several essential functions include participation in processes in order to determine 
the dose-response effect and partial agonist activity which is mediated by opposing 
effects of varying cellular levels of coactivators and corepressors (Szapary et al., 1999). 
The coactivators of steroid hormone receptors possess intrinsic chromatin remodeling 
functions, allowing RNA polymerase II activation and link ERs to the basal transcription 
machinery (Freedman, 1999). While the corepressors in contrast to the coactivators, 
repress the basal transcription in the unliganded status. 
Around one third of genes in humans that are regulated by ERs do not contain ERE-like 
sequences. This indicates there is an alternative pathway of ER action. Promoting ER 
transcription by interacting transcription factor complex containing an AP-1 site, the 
cognate binding site for the transcription factors jun and fos, via protein-protein 
interaction, with ERs (Bjomstrom et aL, 2005). Several genes are activated through this 
pathway such as collagenase (Webb et al., 1995) and cyclin D1 (Liu et al., 2002; Sabbah 
et al., 1999). There is no direct interaction between ERs and ERE as well as no direct 
binding to DNA. Although there is no DNA binding occurred between ERs and ERE, 
the DBD of receptors are frequently involved. DBD may be required for proper protein-
protein interactions or it may involve in recruiting additional co-regulatory proteins to 
the promoter region (Beato et al., 2000). 
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Figure 1.2 Function domains of oestrogen receptor (ER). Structure of ER is divided into 
six modular domains: A/B, C, D, E and F. AF-1 and AF-2 are the transcription 
activation functions 1 and 2. Solid lines indicate the function of each domain. (Beato et 
al., 2000; Rollerova et al., 2000) 
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1.2.2.2 Non-genomic Pathway 
Oestrogen can also elicit non-genomic effects which generally take place in seconds to 
minutes and are too rapid to be accounted for by the activation of RNA and protein 
synthesis. The rapid nitric oxide release in vasculature and nervous system suggested the 
presence of cell surface ERs which linked to intracellular signal transduction pathways. 
In 1970s, Pietras and Szego (1977) first described membrane binding sites for 
oestrogens and described a non-genomic mechanism for calcium influx in endometrial 
cells (Ho et al., 2002). Oestrogens induced a fast rise in free [Ca^^Ji which was due to 
influx of external Ca^^ and/or release of Ca^^ from intracellular Ca^^ store (Morley et aL, 
1992). The non genomic actions also include insensitivity to inhibitors of DNA 
transcription or protein synthesis (actinomycin D or cycloheximide) and recruitment of 
membrane or cytosol localized signaling components (Marino et al” 2005). 
Recently, reports demonstrated that oestrogens can activate MAPK signaling pathway 
through the involvement of integrally linked ER and membrane coupled tyrosine kinase 
in several cell types, including breast cancer, endothelial, bone and neuroblastoma cells 
(Bjomstrom et al., 2005). There is also increasing evidence showing that some of the 
vascular protective effects of oestrogens are mediated by ERo: through a non-genomic 
mechanism involving activation of endothelial nitric oxide synthase by oestrogens 
through the MAPK and PI3K-Akt pathway (Chambliss et al., 2002; Mendelsohn, 2000b; 
Simoncini et al., 2000). Stimulation of adenylate cyclase activity and cAMP production 
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are also reported as one of the non-genomic actions of oestrogen (Gu et al., 1996; Ho et 
al., 2002; Le Mellay et al., 1997; Morley et al., 1992). 
The putative membrane oestrogen receptors responsible for the rapid non-genomic 
activity are still not identified yet. However, indirect evidences have suggested both 
classic ERa and ER/3 (Hall et al., 2001), as well as a non-classical ER (Revankar et al., 
2005) were present on the surface of several target cells. 
Since the classical ERs do not contain any stretch of hydrophobic transmembrane 
domains, and have no intrinsic kinase or phosphatase activity and even lack of 
myristoylation sites for being recruited into the membrane, they were at first not 
accepted as subtype of membrane-associated ER (Manavathi et al., 2006). Nevertheless, 
data have revealed that there are several post-translational modifications on ERo: which 
could contribute to membrane translocalization. By the use of antibodies against ERo; 
membrane ERa was detected and making it likely that nuclear and membrane ERce 
proteins are highly related. Actually, there are growing evidences suggesting that non-
nuclear ERa signaling involves membrane associated heterotrimeric G proteins (Benten 
et al” 2001; Revankar et al., 2005). It was found that rapid increase of eNOS in 
endothelial cells activated by oestrogens can be inhibited by ER antagonist ICI 182,780 
or pertussis toxin specific for Gi. The G-protein coupled membrane ERa is also involved 
in the rapid oestrogen signaling of increasing [Ca ]i in endothelial cells. The membrane 
ERo: can somehow explain most of the oestrogen signaling outcomes, however further 
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definition of the nature of ERo; e.g the differences between the membrane and the 
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/ c a s c a d e s ^ ,〜）{ 
Figure 1.3 Schematic illustration of ER signaling mechanisms including both genomic 
and non-genomic pathways. Genomic pathways: 1. The ligand-bound ERs dimerize and 
translocate to the nucleus and undergo subsequent gene transcription with related 
coactivators and corepressors recruited. 2. The ligand-bound ER transcript genes 
through the interaction with transcription factor complex (TR). Non-genomic pathway: 3. 
A rapid signaling pathway through multiple protein kinase cascades. (Bjomstrom et al., 
2005) 
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1.3 Aims of Study 
It is well acknowledged that mast cell activation is one of the key parameters to be 
considered when studying inflammation. The mast cells can be triggered by anti-IgE or 
basic secretagogues (e.g. substance P and compound 48/80) and mediators (e.g. 
histamine, serotonin) released from the activated mast cells represent a degree of mast 
cell degranulation activity. As oestrogens are related to several inflammatory diseases 
especially at postmenopausal stage, several researchers had studied the interactions 
between oestrogens and mast cells. 
Contradictory results however were obtained. Cocchiara et al. (1990) reported that 
oestradiol was able to enhance anti-IgE induced histamine release of both Wistar rat 
peritoneal mast cells and sensitized human basophils in dose-dependent manners, 
reaching the maximum release of 23% for RPMCs and 41% for sensitized human 
o 
basophils after 30 minutes pre-incubation with 10' M oestrogen. The enhancing effect 
was however not observed when RPMCs were activated with the basic secretagogue 
compound 48/80 or neuropeptide substance P. In contrast, Vliagoftis et al. (1992) 
demonstrated that oestrogen starting at lO'^M was able to augment secretion of 
histamine and serotonin from Sprague-Dawley rat peritoneal mast cells when stimulated 
with compound 48/80 or substance P, but not anti-IgE (Vliagoftis et al., 1992). 
Oestrogen also enhanced histamine release induced by embryonic histamine-releasing 
factor from Wistar uterine mast cells but not the peritoneal mast cells. This suggested 
that mucosal and connective tissue type mast cells provided different responses towards 
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oestrogen preincubation (Cocchiara et al., 1992). Mast cells and basophils cell lines 
were also reported to have enhanced mediators (granular /5-hexosaminidase and L T C 4 ) 
release by oestrogen preincubation when challenged together with anti-IgE (Zaitsu et al., 
2007). 
In order to study the effect of oestrogens in mast cells and to obtain a better picture of 
their involvement in mast cell activation process amongst a series of contradicting 
results reported in previous literatures, effects of a range of oestrogen receptor agonists 
and selective oestrogen receptor modulators (SERMs) on secretagogues mediated 
histamine release from antigen-stimulated mast cells were examined. The acute effects 
of oestrogens were also investigated. Membrane impermeable oestrogen and drugs for 
inhibiting transcription and translation processes were employed to evaluate if the 
oestrogenic effects were mediated through non-genomic pathways. Since substantial 
amounts of rat peritoneal mast cells (RPMCs) could be isolated and purified easily, plus 
most of the previous reports had made use of the RPMCs in their studies, we, hence, 
used them to perform our experiments. A better understanding of the oestrogenic actions 
on mast cells would explain the epidemiological difference of several diseases (e.g. 
osteoporosis, interstitial cystitis) occurrences in different genders. 
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2. Materials and Methods 
2.1 Materials 
All materials were purchased from commercial sources as listed. The abbreviations 
shown in brackets will be used in later chapters. 
2.1.1 Drugs 
2.1.1.1 Oestrogen Receptor Agonists and Antagonists 
Oestrogen Agonists 
17/3-Estradiol Sigma Chemicals 
(3-Estradiol 6-(0-carboxymethyl)oxime: Sigma Chemicals 
BSA 
(BSA-conjugated estradiol) 
4,4,，4”-(4-Propyl-[l//]-pyrazole-l,3,5- Tocris Cookson 
triyl)rr/5phenol 
(PPT) 
Diarylpropionitrile Tocris Cookson 
(DPN) 
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Oestrogen Antagonists 
7o;17i(3-[9[(4,4,5,5,5- Tocris Chemicals 
P entafluorop entyl) sulfinyl] nonyl] estra-
l，3,5(10)-triene-3,17-diol 
(ICI 182,780) 
MPP dihydrochloride Tocris Chemicals 
(MPP) 
Selective Oestrogen Receptor Modulators 
Tamoxifen Tocris Chemicals 
Raloxifene Tocris Chemicals 
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Selective Oestrogen Receptors Modulators (SERMs) 
/ = \ CH3 
V _ f / � C H 3 
/ A \ j Tamoxifen 
j y ^ � H 
H O Raloxifene 
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OH V OH 
DPN PPT 
Fig. 2.1 Chemical structures of ER agonists and SERMs used in this study 
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Oestrogen receptors antagonists 
OH rfJA 
I T I H O p 
F3C 
ICI 182,780 
/ ^ .2HC1 P 
" c ^ ^ ^ C K � o 
H3C ^ ^ 
MPP 
Fig. 2.2 Chemical structures of ER antagonists used in this study 
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2.1.1.2 DNA Transcription and Translation Blockers 
Actinomycin D Sigma Chemicals 
Cylcoheximide Sigma Chemicals 
2.1.1.3 Mast Cell Secretagogues 
Sheep Anti-Rat IgE (Anti-IgE) ICN Biomedicals 
Compound 48/80 Sigma Chemicals 
Substance P Sigma Chemicals 
2.1.2 Materials for Histamine Assay Experiments 
2.1.2.1 Materials for Rat Sensitization 
Chicken egg white albumin (lyophilized) ICN Biomedicals 
(OVA) 
Adsorbed diphtheria, tetanus, pertussis Aventis Pasteur 
vaccine 
Aluminium hydroxide Merck 
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2.1.2.2 Materials for Ovariectomy surgery 
Pentobarbital sodium 20% Alfasan 
2.1.2.3 Materials for Buffers 
Heparin Leo, Denmark 
Bovine serum albumin Sigma Chemicals 
(BSA) 
Sodium chloride Merck 
(NaCl) 
N-[2[hydroxyethyl] piperazine-N，-[2- Sigma Chemicals 
ethanesulfonic acid] 
(Hepes) 
D-(+)-Glucose BDH Laboratory Supplies 
Potassium chloride BDH Laboratory Supplies 
(KCl) 
Sodium dihydrogen orthophosphate BDH Laboratory Supplies 
(NaH2P04.2H20) 
Calcium chloride-dihydrate Merck 
(CaCl2.2H20) 
di-Potassium hydrogen orthophosphate tri- BDH Laboratory Supplies 
hydrate 
(K2PO4.3H2O) 
Magnesium chloride hexahydrate Merck 
(MgCl2.6H20) 
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2.1.2.4 Materials for Histamine Release Assay 




Sodium Hydroxide Mallinckrodt 
(NaOH) 
Sulphuric Acid Merck 
(H2SO4) 
Methanol Lab-Scan 
Perchloric Acid (70%) Mallinckrodt 
Brij 35 Solution Sigma Chemicals 
Hydrochloride Acid BDH Laboratory Supplies 
(HCl) 
2.1.2.5 Miscellaneous 
Percoll GE Healthcare 
Aldan Blue Sigma Chemicals 
Trypan Blue Sigma Chemicals 
Dimethylsulphoxide Sigma Chemicals 
(DMSO) 
10ml Polystyrene disposable tubes Starstedt 
Microcentrifuge tubes Eppendorf 
Pasteur Pipettes Samco 
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Disposable 30ml syringe Terumo 
Disposable needles Terumo 
Haemocytometer Menzel-Glaser 
Micro-pipettes Eppendorf 
Micro-pipette tips Healthcare Diagnostics 
Histamine Auto-analyzer 3 Bran+Luebbe 
(AA3) 
Hot water bath tank Grant 
CR422 centrifuge Jouan 
2.1.3 Materials for Oestrogen Receptors Identification 
2.1.3.1 Oestrogen Receptors Expression 
2.1.3.1.1 Materials for RNA Extraction 
TRIZOL Reagent In vitro gen 
Chloroform BDH Laboratory Supplies 
Isopropanol In vitro gen 
Ethanol 75% Riedel-de Haen 
Diethyl Pyrocarbonate (DEPC) Sigma Chemicals 
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2.1.3.1.2 Materials for cDNA Construction by RT-PCR 
1 OX DNase I Reaction Buffer Invitrogen 
DNase I Invitrogen 
EDTA solution Sigma Chemicals 
Oligo (dT)i2-i8 Invitrogen 
dNTP Mix Invitrogen 
5X First-Strand Buffer Invitrogen 
DTT Invitrogen 
RNaseOUT Invitrogen 
SUPERSCRIPT 丁MII reverse transcriptase Invitrogen 
RNAsin® Ribonuclease Inhibitor Promega 
Heparinase I Sigma Chemicals 
2.1.3.1.3 Materials for PCR 
dNTP Mix Invitrogen 
MgCli Invitrogen 
1 OX PCR buffer Invitrogen 
Oestrogen receptor alpha primers Invitrogen 
Sense (5' to 3'): AAT TCT GAC AAT 
CGA CGC CAG 
Antisense (5' to 3'): GTG CTT CAA CAT 
TCT CCC TCC TC 
Oestrogen receptor beta primers Invitrogen 
Sense (5' to 3'): TTC CCG GCA GCA 
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CCA GTA ACC 
Antisense (5’ to 3，)： TCC CTC TTT GCG 
TTT GGA CTA 
GAPDH primers Invitrogen 
Sense (5' to 3'): ACC AC A GTC CAT 
GCC ATC AC 
Antisense (5’ to 3')： TCC ACC ACC CTG 
TTG CTG TA 
Platinum® Taq DNA Polymerase Invitrogen 
2.1.3.1A Materials for Agarose Gel Electrophoresis 
Agarose Invitrogen 
Ethidium bromide Invitrogen 
lOObp control ladder Invitrogen 
Loading dye Invitrogen 
Tris-base Sigma Chemicals 
Glacial acetic acid BDH Laboratory Supplies 
Ethylenediaminetetraacetic acid Sigma Chemicals 
(EDTA) 
2.1.2.1.5 Miscellaneous 
RoboCycler® Gradient 96 thermo-cycler Stratagene 
FluorChem™ 8000 Gel Documentation Alpha Innotech Inc. 
System 
Horizon® 11.14 Gel tank and power pack Life technologies 
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M-240R microcentrifuge Boeco Germany 
2.2 Histamine Assay Experiments 
2.2.1 Preparation of Buffers 
The buffer solutions used in our experiments were prepared following the ingredients 
below. All ingredients were dissolved in distilled water. 
Full Hepes Buffer (FHB) 137mM NaCl，5.56mM Glucose, 12mM 
Hepes，2.7mM KCl, 0.4mM NaHzPO*, 
ImM CaCl2, make up to IL 
(pH adjusted to 7.4) 
Heparinised buffer Full Hepes Buffer with 0.1ml heparin 
added per 50ml Buffer 
BSA-Hepes Buffer Img/ml bovine serum albumin (BSA) 
added to Full Hepes Buffer 
lOX Calcium-free Hepes Buffer 1.37M NaCl, 55.6M Glucose, 120mM 
Hepes, 27mM KCl, 4mM NaH2P04, make 
up to 100ml 
(pH adjusted to 7.4) 
Ortho-phthlaldialedyde 0.6mg/ml OPT added to distilled water 
(OPT) 
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2.2.2 Preparation of Stock Solutions 
2.2.2.1 Preparation of Mast Cell Secretagogues Stock Solutions 
The lyophilized anti-rat IgE was reconstituted in 2ml distilled water to produce the anti-
rat IgE stock. Compound 48/80 and substance P were dissolved in distilled water to 
concentration of lOmg/ml and ImM respectively. All stock solutions were aliquoted and 
kept at -20°C until before shortly before use. 
2.2.2.2 Preparation of Oestrogens Stock Solutions 
17/5-Estradiol, tamoxifen, raloxifene, DNP, PPT, MPP and ICI 182,780 were dissolved 
in DMSO to prepare a 50mM stock and were stored in aliquots at -20°C. BSA-
conjugated estradiol was dissolved in distilled water to concentration of 50mM and 
stored frozen in small aliquots. Shortly before use, these stock solutions were diluted to 
appropriate concentrations for reactions using FHB. 
48 
Chapter 2: Materials and Methods 
2.2.3 Animals and Rat Peritoneal Mast Cell Isolation 
2.2.3.1 Animals 
In our experiments, peritoneal mast cells from Sprague Dawley (SD) rats of both 
genders were used. All rats were bred within the animal house of the Chinese University 
of Hong Kong and were kept at approximately 25°C in 12 hour light/dark cycles until 
required. 
2.2.3.2 Rats Sensitization 
SD rats weighing 180-200g were injected intraperitoneally with 0.7ml suspension 
composed of lOmg ovalbumin, Ig A1(0H)3, 2ml pertussis toxin (16 I.U. Bordetella 
pertussis) in 5ml PBS (O.OIM). All of the above ingredients were completely dissolved 
by continuous stirring. After sensitization process, all rats were kept in the animal house 
for further seven to eight weeks before they were used for the rat peritoneal mast cell 
experiments. 
2.2.3.3 Ovariectomy Surgery 
Ovariectomy surgery was done following procedures by Olson (1986). Briefly, female 
SD rats were anesthetized by 20% pentobarbital in a concentration of 0.2ml/100g three 
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weeks after being sensitized. Bilateral ovariectomy was done. Fur covered around both 
thighs was shaved. Skin, adipose and muscle layers around the thigh were cut open 
using sterile forceps and surgery scissors. The ovary duct was tied and the ovary was 
removed. Skin layer was sewed to close the wound. The same operation was done on 
another side. Rats undertaken ovariectomies were kept for further four weeks before 
used for the rat peritoneal mast cell experiments. The above procedures were done on 
other groups of female SD rats, except the removal of ovaries, in parallel with the 
ovarectomized rats at the same time. These groups were considered as the control groups, 
the Sham-operated rats. 
2.2.3.4 Isolation of Rat Peritoneal Mast Cells 
Rats were first lightly anaesthetized with diethyl ether and then sacrificed by 
decapitation and exsanguination. The fur covering the abdomen was removed and 25ml 
of heparinised buffer was injected intraperitoneally. After 2 minutes of massage, the rats 
were cut open along the midline of the abdominal wall. The heparinised buffer with 
peritoneal cell suspension was collected using a Pasteur pipette and transferred into 
polystyrene tubes. 
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2.2.3.5 Purification of Mast Cells 
Peritoneal cell suspension collected was centrifuged for lOOOrpm at 4°C for 5 minutes. 
Cell pellet was collected and re-suspended in BSA-Hepes Buffer and centrifuged for 
lOOOrpm at 4°C for another 5 minutes. The cell suspension was then purified by 
centrifugation through isotonic Percoll gradient separation. The Percoll solution was 
prepared by addition of 3.6ml of Percoll to 0.4ml lOX calcium-free buffer. Peritoneal 
cells were then re-suspended in 1ml BSA-Hepes Buffer, added to the Percoll solution 
and mixed by up-and-down inversion of polystyrene tube. A further 1ml BSA-Hepes 
Buffer was gently layered on the cell mixture. The cells were then purified through 
Percoll density gradient by centrifuge for 150g at 4°C for 25 minutes (Mackay and 
Pearce, 1992). Purified rat peritoneal mast cells were obtained as a cell pellet, other 
impurities and unwanted cells were separated from the mast cells in different density 
layers generated by the Percoll solution during centrifugation. Mast cells were first 
washed by centrifugation (lOOOrpm, 4°C，5 minutes) in BSA-Hepes Buffer and 
subsequently with FHB. 
2.2.3.6 Determination of Mast Cell Number and Viability 
In order to confirm the purification of mast cells, 25/xl of cells were incubated with 65/xl 
of BSA-Hepes Buffer and lOjitl aleian blue dye at 37°C for 10 minutes. After incubation, 
the cells were observed under a light microscope. Mast cells containing cytoplasmic 
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granules and a single nucleus, took up the dye and appeared distinct blue colour. With 
the help of a haemocytometer, the number of mast cells in the sample was then 
determined by counting both stained and unstained cells. The purity of mast cells 
employed in the current study was over 95%. 
The trypan blue exclusion test was used to determine cell viability. 50/xl cell was 
incubated with 50jitl trypan blue at ?>TC for 10 minutes. Only dead cells would take up 
the blue dyes while viable cells would not. The numbers of dead and viable cells were 
then counted under light microscope using haemocytometer. The viability of the purified 
mast cells used in the current study was over 98%. 
2.2.4 Histamine Release Assay and Histamine Measurement 
2.2.4.1 Histamine Release Assay 
3 X 10^ - 9 X 10^ of purified RPMCs were suspended in FHB in polystyrene tubes and 
pre-incubated in 37°C water bath for 10 minutes. At the same time, tested oestrogen 
related drugs and mast cell secretagogues of different tested concentrations were pre-
incubated in polystyrene tubes under the same condition as the RPMC. 
After 10 minutes, 200jLtl of the RPMC suspension were added to different polystyrene 
tubes containing 200/xl of different concentrations of tested drugs. Each tube contained 
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around 0.3 X 10^ cells for completing the histamine release assay. A further 20/xl mast 
cell secretagogue was added to the reacting tubes either immediately or 10 or 30 minutes 
after the addition of cells. The tubes were shook gently for complete mixing of cells and 
drugs. At the end of further 10 minutes incubation, 1ml of cold FHB was added to each 
tube to stop the reaction. Throughout the whole reaction, all reacting tubes were shook 
gently and continuously. 
The cell pellet and supernatant were separated by centrifugation (lOOOrpm, 4°C, 5 
minutes). Supernatant was then transferred to another clean polystyrene tube. Distilled 
water of the same volume as the supernatant was added to the tubes containing cell 
pellets only. A further SOjul of 70% perchloric acid was added to both supernatant and 
cell pellets tubes and vortexed in order to break down the cells and allow total histamine 
content in cells to be determined afterwards. 
2.2.4.2 Fluorescence Assay of Histamine 
Both cell pellet and supernatant samples were centrifuged (2000rpm, 25°C, 20 minutes) 
to remove cell debris. The samples were then diluted appropriately and assayed by the 
Bran + Luebbe AA3 system (Atkinson et al., 1979). Samples were extracted by solvents 
including Butan-l-ol, heptane, sodium hydroxide, OPT and sulphuric acid under the 
control of AA3 system. Histamine reacted with OPT to form a fluorescence complex 
which could be excited at 355mn wavelength and detected at 460nm wavelength. 
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2.2.5 Calculation of Histamine Release Level and Inhibition 
Histamine release was calculated as the percentage of total cellular histamine released. 
The formula is as follow: 
Histamine release percentage (HR %) = Histamine (supernatant) X 100% 
Histamine (supernatant) + Histamine (ceii) 
Where Histamine (supernatant) = histamine released into the supernatant, 
Histamine (ceii) = unreleased histamine in cell 
All histamine release values were corrected with the corresponding spontaneous 
histamine release (basal histamine release from RPMC in buffer alone without 
stimulation by any stimuli) by subtracting the spontaneous value. 
The degree of inhibition by drugs on secretagogues induced histamine release was 
calculated as follow: 
Inhibition (%) = HR% (secretagogue alone) — HR% (secretagogue + drug) X 100% 
H R % (secretagogue alone) 
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2.2.6 Statistics Analysis 
All experimental data were expressed as mean 士 standard error of mean (SEM) for n 
observations. Paired 厂test was used when comparing control and tested cells, while 2-
way ANOVA was used when more than two comparable values were present. 
2.3 Oestrogen Receptors Identification 
2.3.1 Oestrogen Receptors Expression 
2.3.1.1 Preparation of Buffers 
5Ox TAE buffer 24.2g Tris-base, 5.71ml glacial acetic acid, 
3.72g Sodium EDTA, make up to 100ml 
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2.3.1.2 Isolation of Mast Cell mRNA 
Isolation of mast cell mRNA was done by following Cutolo et al. (2001). Briefly, 1 X 
10^ purified RPMCs were pelleted by centrifugation (lOOOrpm, 4°C, 5 minutes) and 
lysed by shearing force induced by repetitive pipetting in 1ml TRIZOL Reagent. The 
homogenized sample was then incubated at room temperature for 15 minutes. 0.2ml of 
chloroform was added to the sample and mixed thoroughly by shaking the tube 
vigorously for 15 seconds. The sample was then allowed to settle down at room 
temperature. After 3 minutes of incubation, the sample was centrifuged (12000g, 4°C, 15 
minutes) and was separated into 3 different layers. The top aqueous phase contained our 
desired RNA and was transferred to a fresh tube in which 0.5ml isopropanol was added 
and mixed to precipitate RNA. After mixing, the sample was incubated at room 
temperature for 10 minutes before precipitation of RNA by centrifugation (12000g, 4°C, 
10 minutes). RNA sample was observed as a gel-like pellet at the bottom. Supernatant 
was removed and the RNA pellet was washed with 1ml 75% ethanol by vortexing and 
subsequently centrifuged at 7500g at 4°C for 5 minutes. All supernatant was removed 
and the RNA pellet was allowed to be air-dried for 5 minutes. The dried RNA pellet was 
then dissolved in DEPC water for later RNA quantification. 
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2.3.1.3 Heparinase Treatment 
A l|Lig aliquot of RNA was incubated with 5U of Heparinase I in a reaction mixture 
containing 5mM Tris pH7.5, ImM CaCb, 40U RNAsin, for 2 hour at room temperature 
(Gilchrist et al., 1997). 
2.3.1.4 Construction of Mast Cell cDNA by RT-PCR 
To start with, 1/xg RNA sample was incubated with 0.5/xl of lOX DNase I Reaction 
Buffer and 0.5/xl DNase I at room temperature for 15 minutes. The reaction was then 
stopped by addition of O.Sfil EDTA solution and followed by heating at 65°C for 10 
minutes. After heating, 5/xl sample was extracted and transferred to an RNase-free 
micro-centrifuge tube and 0.5/xl Oligo (dT)i2-i8 together with 0.5/xl dNTP mix were 
added. The mixture was heated to 65°C for 5 minutes then chilled quickly on ice. 
Volume of 2/xl 5X First-Strand Buffer, 1/xl of O.IM DTT and 0.5/xl RNaseOUT were 
added to the mixture and further incubated at 42°C for 2 minutes. Lastly, 0.5/xl 
SUPERSCRIPT II was added to the mixture and further incubated at 42°C for 50 
minutes. The reaction was then inactivated by heating at 70°C for 15 minutes. cDNA 
was then prepared for later PCR process. 
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2.3.1.5 Amplification of Oestrogen receptors cDNA by PCR method 
Reaction mixture containing 19jLtl water, ljU-1 of 50mM MgCh, 2.5/>tl of lOX PCR buffer, 
0.5/xl of lOmM dNTP，0.5/>tl sense primer, 0.5/zl anti-sense primer, 0.2/>tl Taq DNA 
Polymerase and l/xl template was subjected to PCR process. The PCR cycle was set with 
45 cycles of 95®C for 1 minute, 5TC for 30 seconds and iTC for 1 minute, followed by 
10 minutes incubation at 72°C (Kuiper et al., 1997). PCR products were then kept at 4°C 
for later DNA gel analysis. The primers design and PCR conditions were based on 
(Kuiper et al, 1997). 
2.3.1.6 Agarose Gel Electrophoresis 
1% agarose gel was prepared freshly before use. The 1% agarose gel was obtained by 
dissolving Ig agarose in 100ml of IX TAE buffer. Ethidium bromide was added to the 
hot agarose gel and mixed well. The gel mixture was then added to the gel tank and was 
allowed to set and cool. 600ml of IX TAE buffer was added to the gel tank to cover the 
cooled agarose gel. PCR products were loaded into the sample wells by mixing lO/il 
sample with l/xl dye. DNA ladder was also loaded by mixing 0.5/xl lOObp ladder, 4.5/xl 
water and O.Sjitl loading dye. Power supply was connected and 130 - 150V voltage was 
set and the gel was allowed to run until it reached the marking. The gel was then 
photographed using FluorChem™ 8000 Gel Documentation System. 
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3. Effects of Oestrogens on Immunological Induced Histamine 
Release from Rat Peritoneal Mast Cells 
3.1 Introduction 
Oestrogens are important for maintaining overall health including prevention of 
osteoporosis and reduced cardiovascular diseases, therefore postmenopausal women are 
often more susceptible to the above diseases. In order to improve their situations, 
synthetic oestrogen, known as selective oestrogen receptor modulators (SERMs)，are 
designed. SERMs are synthetic compounds that block the growth of oestrogen 
dependent breast cancers while at the same time exhibit unique profiles of oestrogen like 
effects in other tissues, such as uterotropic activity and bone loss prevention. It can 
induce three-dimensional structural changes of ER that lead to different multitude of 
•estrogenic activities that specifically function for each target cell type. This mixed 
agonist/antagonist oestrogen behaviors make the SERMs importantly used as oestrogen 
replacement during the hormone replacement therapy on postmenopausal women (Webb, 
2002). 
SERMs exhibit a mixed oestrogenic/anti-oestrogenic effects in different target tissues. 
They can promote its anti-oestrogen effect by inhibiting ER action at EREs through the 
blocking of AF-2 activity on the E domain of ER. Generally, there is a hydrophobic 
cleft on the E domain in order to act as a binding site for coactivators. When a SERM 
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binds to the LBD on E domain, part of it is protruded through the surface and interferes 
the hydrophobic cleft which results in removing part of the binding site for coactivators. 
Besides inhibiting ER action by blocking coactivators' recruitment, SERMs can promote 
corepressors recruitment (Osborne et al., 2000; Webb, 2002). Yet, the mechanism on 
how corepressors are recruited still remains unclear. SERMs also exhibit oestrogenic 
effect in target tissues. Data supported that the SERMs behave like oestrogens at 
classical EREs by following ER-a to bind to DNA and utilize AF-1 to recruit 
coactivators. SERMs do not behave as agonists in the presence of ER-/5. This can be 
explained that ER-jS AF-1 is relatively weak in coactivators binding. 
Tamoxifen, the generation SERMs is most widely used for the treatment of women 
with breast cancer. However, it is known to possess mixed oestrogenic and anti-
oestrogenic activities that are species-, tissue-, cell- and even gene-specific. Its most 
widely recognized adverse effects are those related to the stimulatory effects on 
endometrium including proliferation of the endometrium, formation of endometrial 
polyps, hyperplasia and cancer. Analogues of tamoxifen: toremifene, droloxifene, 
idoxifene, TAT-59 and GW5638 have been synthesized and developed to various stages 
including clinical trials and commercialization. Raloxifene is the generation of 
SERMs which bind to both ER-a and ER-/3. Clinical studies in postmenopausal women 
have confirmed the protective effect of raloxifene on bone However, raloxifene still 
exert some weak but significant stimulatory effects on the proliferation of human breast 
cancer in vitro (Labrie et al., 2002). 
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Oestrogen receptor agonists PPT and DPN were also employed as tools to study the 
oestrogenic effects on RPMCs. PPT is a selective ER-o: agonist, which have a 410 fold 
of selectivity on ER-a than ER-/3. DPN behaves as ER-/3 agonist, exhibiting a 70-fold 
selectivity over ER-o:. Both of them have shown ability to exert vasodilatory effect as 
mediated by ITjS-estradiol, where PPT has a significantly greater vasodilatory effect than 
DPN (Montgomery et al” 2003). The high selectivity of oestrogen receptor agonists 
allow respective oestrogen receptors to be studied individually. 
We investigate if there were differences in response between sexes, as according to 
epidemiological study, male has a higher cardiovascular risk than pre-menopausal 
females (Stork et al., 2004). Ovariectomized rats were also used as a study model to 
mimic the postmenopausal stage and checked if mast cells from these animals 
demonstrate different response to oestrogenic agents. 
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3.2 Materials and Methods 
The methods and materials employed are as described in chapter 2. Anti-IgE 
concentration of 1/1000 was used for stimulation of the purified RPMCs which induced 
an average of 20%-30% histamine release (Vliagoftis et al., 1992). All results are 
corrected for spontaneous release in buffer alone, while anti-IgE induced histamine 
releases in the presence of oestrogens are corrected also for the oestrogen induced 
release. 
The highest drug concentrations of various drugs tested in the study varied according to 
their solubility in solvents. When DMSO was used as the solvent to prepare stock 
solutions of drugs, the DMSO concentration in the highest drug concentration test must 
be <0.01%, at which DMSO does not produce any effects on mediator release, as 
confirmed by parallel control tests containing such DMSO dilutions performed with the 
actual experiments. 
Results were analyzed, using paired 广-test, for statistical significance by comparing anti-
IgE induced histamine release in the presence of oestrogenic agents to control release 
induced by anti-IgE alone. Two way ANOVA was employed when comparing the 
effects of oestrogenic agents between two different groups of animals. Differences were 
considered significant when /?<0.05. 
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3.3 Results 
The overall spontaneous release of histamine from purified RPMCs incubated with 
buffer alone did not exceed 20%. A general increase in spontaneous release was 
observed with incubation time. Data are presented as percentage of histamine release 
after correction for the spontaneous release. Anti-IgE induced histamine release in the 
presence of various oestrogen receptor agonists were further corrected for the drug 
mediated histamine release. The degree of inhibitory effect by drugs on activated mast 
cells was also shown. 
3.3.1 Activation of RPMCs by Immunological Stimuli 
3.3.1.1 Effects of Oestrogen Receptor Agonists on Histamine Release from RPMCs 
The oestrogen receptor agonists 17/3-estradiol, PPT and DPN as well as the SERMs 
tamoxifen and raloxifene were incubated with RPMCs of both sexes for 20 minutes. 
There was a 5% — 10% histamine release induced by all oestrogenic agents without any 
dose-dependent tendency (Fig. 3.1 and Fig. 3.2). There were no observable differences 
between oestrogen induced histamine release with different incubation time courses (Fig. 
3.3). Same low level, dose-independent histamine release was also observed from sham-
operated and ovariectomized rats (Fig. 3.4 and 3.5). These low levels of histamine 
release were all significantly higher than the spontaneous histamine release in buffer 
alone. 
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3.3.1.2 Effects of Oestrogen on Anti-IgE mediated Histamine Release from RPMCs 
When 17/5-estradiol pre-treated RPMCs were challenged with anti-IgE, the level of 
histamine release induced were found to be significantly reduced when compared to that 
induced by anti-IgE alone. 17j5-estradiol was incubated with RPMCs for different 
incubation times: 0, 10 and 30 minutes. Results from all three different incubation times 
demonstrated significant inhibitory effects on anti-IgE induced histamine release from 
male RPMCs by 17jS-estradiol (Fig. 3.6 - 3.8). Therefore, in the following experiments, 
10 minutes pre-incubation time of oestrogens with RPMCs was employed to study 
effects of oestrogens on mast cell activation. 
The anti-IgE induced histamine release of male RPMCs was reduced from 15.0 士 1.1 o/o 
to 9.2 士 1.6o/o at the highest drug concentration (lO'^M). The degree of inhibition was 
not dose-dependent and similar results were obtained in both male and female rats (Fig. 
3.7 and Fig. 3.9) as well as in ovariectomized female rats and their sham-operated 
controls (Fig. 3.11). The anti-IgE induced histamine release of female RPMCs was 
reduced from 14.3 士 0.9o/o to 6.2 士 1.9o/o at lO'^M drug concentration, while anti-IgE 
induced histamine release of ovariectomized and sham-operated RPMCs were reduced 
from 32.5 ± 1.1% to 24.6 士 2.0o/o at lO'^M concentration and 27.5 士 1.5o/o to 18.1 士 1.1 o/o 
at lO'^M concentration respectively. When the percentage inhibitory values of histamine 
release between male and female rats were compared, similar degree of inhibitions with 
no significant differences was observed. Maximum inhibitory values of 51.0 土 8.2o/o at 
lO'^M and 59.2 士 17.0o/o at lO'^M were observed in male and female rats respectively 
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(Fig 3.10). There were also no significant differences of inhibition between 
ovariectomized and sham-operated rats. The highest inhibitory values from sham 
operated and ovariectomized rats were 50.4 土 8.0o/o at lO'^M and 43.9 士 12.1o/o at lO'^M 
respectively (Fig 3.12). 
3.3.1.3 Effects of Selective Oestrogen Receptor Modulators on Anti-IgE Mediated 
Histamine Release from RPMCs 
Primary and secondary generations of selective oestrogen receptor modulators (SERMs), 
tamoxifen and raloxifene, were tested. When tamoxifen pre-treated RPMCs from male 
SD rats were challenged with anti-IgE, the histamine release was significantly reduced 
when compared with that induced by anti-IgE alone. There was no dose dependent 
tendency observed in RPMCs from different sources. The highest reduction of anti-IgE 
induced histamine release of male RPMCs was from 30.5 士 4.5o/o to 18.4 士 5.3o/o at 
o 
concentration of 10' M (Fig. 3.13). Similar inhibitory effect was observed in RPMCs 
from normal (Fig. 3.14), sham-operated and ovariectomized female rats as well (Fig. 
3.16), the highest reduction of anti-IgE induced histamine releases were from 38.5 士 
2.6% to 26.5 ± 2.0% (lO'^M), 18.6 士 2.9o/o to 9.0 士 2.7o/o (10"^M) and 21.5 土 4.1o/o to 
12.8 士 4.50/0 (lO'^M) respectively. The highest inhibitory values observed from male and 
female RPMCs was 42.3 士 10.8o/o and 31.0 士 4.40/0 respectively with no significant 
difference between the two groups of animals (Fig. 3.15). The highest inhibitory values 
from RPMCs of sham-operated and ovariectomized rats were 69.0 士 15.6o/o and 41.4 士 
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6.6% respectively (Fig. 3.17) and significant difference between the inhibitory actions of 
tamoxifen between the two groups were not observed. 
Raloxifene pre-treated RPMCs from male SD rats demonstrated an apparently biphasic 
effect on anti-IgE induced histamine release. Raloxifene demonstrated a tendency to 
8 6 
inhibit anti-IgE induced histamine release between 10" M to 10' M, whereas an 
enhancing effect was observed at lO'^M (Fig. 3.18). Histamine release was reduced from 
13.1 士 1.4% to 7.4 士 1.90/0 at lO'^M then increased to 30.1 士 5.0o/o as raloxifene 
concentration was increased to lO'^M. In normal female rats (Fig. 3.19), anti-IgE 
induced histamine release from female RPMCs was significantly suppressed by lO'^M 
and lO'^M of raloxifene from 20.8 ± 1.10/0 to 10.6 士 2.8o/o but was enhanced and reached 
35.5 士 2.8o/o at lO'^M. A similar biphasic action of raloxifene on anti-IgE induced 
histamine release was also observed in sham-operated female rats, with anti-IgE induced 
histamine release was first reduced from 23.7 士 4.2o/o to 10.2 士 I k T A at lO'^M then 
increased to 27.5 士 1.8o/o at lO'^M in sham-operated rats. The result from ovariectomized 
rats was first reduced from 19.7 士 2.1o/o to 8.4 土 l.io/o at lO'^M then increased to 34.6 士 
1.7% at lO'^M. The highest inhibition values obtained from male, female, sham-operated 
and ovariectomized rats were 69.5 士 18.1o/o (lO'^M), 40.8 士 4.1o/o (lO'^M), 63.7 士 16.1o/o 
o o 
(10" M) and 55.1 士 9.5o/o (10" M) respectively. There was a significant difference 
between percentage inhibition of anti-IgE induced histamine release from male and 
female RPMCs at lO'^M raloxifene (Fig. 3.20). At lO'^M raloxifene, percentage 
inhibition in sham-operated and ovariectomized RPMCs was significantly different as 
well (Fig. 3.22). 
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3.3.1.4 Effects of Selective Oestrogen Agonists on Anti-IgE Mediated Histamine 
Release from RPMCs 
The effects of specific oestrogen receptor a (ER-o;) and oestrogen receptor (3 (ER-/5) 
agonists, PPT and DPN respectively, on anti-IgE induced histamine release were 
investigated. In the male rats, a general reduction of anti-IgE induced histamine release 
was observed and significant inhibition was observed at the highest tested concentration 
of lO'^M (Fig. 3.23) and the anti-IgE induced histamine release was reduced from 27.7 士 
5.4% to 15.7 士 5.8o/o. In the normal, sham-operated and ovariectomized female rats, 
maximum inhibition again was observed at lO'^M with reduction from 39.8 士 4.1o/o to 
26.4 士 3.90/0, 19.7 土 4.2o/o to 8.7 士 2.3o/o and 18.8 土 4.8% to 11.0 士 l-P/o respectively 
(Fig. 3.24 and Fig. 3.26). There was no significant difference observed between the 
inhibitory potency of PPT on anti-IgE induced histamine release from sham-operated 
and ovariectomized rats. 
ER p agonist (DPN) demonstrated similar effect as PPT. Significant inhibitory effect 
was observed in male RPMCs at the highest tested dose (lO'^M) (Fig. 3.28) with a 
general but non-significant reduction at the lower dose levels. The anti-IgE induced 
histamine release was reduced from 31.4 士 5.1o/o to 18.1 士 3.3o/o at lO'^M. While along 
the tested drug concentration, significant inhibitory effect on histamine release from 
normal (Fig. 3.29), sham-operated and ovariectomized RPMCs was observed (Fig. 3.31). 
The anti-IgE induced histamine releases were reduced from 38.8 士 1.3o/o to 27.5 士 0.4o/o， 
28.8 士 3.2o/o to 21.1 土 2.2o/o and 28.4 士 1.7o/o to 17.7 士 2.8o/o in normal, sham-operated 
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and ovariectomized female rats at the highest test drug concentration of lO'^M 
respectively. Again, no dose-dependent tendency was observed in all RPMCs from 
different sources. Histamine release data obtained from sham-operated and 
ovariectomized rats did not show any significant difference. The corresponding highest 
inhibitory values by lO'^M DPN in sham-operated and ovariectomized rats were 34.3 士 
7.3% and 38.5 士 6.0o/o (Fig. 3.32). The inhibition range, induced by DPN on anti-IgE 
induced histamine release, was observed from 12.2 士 12.0o/o to 40.2 士 in male and 
19.7 士 1.60/0 to 28.9 士 2.80/0 in female (Fig. 3.30). 
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3.4 Discussion 
From our studies, all the tested oestrogen receptor agonists and SERMs were able to 
induce a basal histamine release of 5-10% by themselves. This low level of histamine 
release was observed in RPMCs of male, female, sham-operated and ovariectomized rats, 
indicating that the level of endogenous oestrogens was not a factor influencing the weak 
mast cell activating action of oestrogenic agents. Although previous studies on rat 
peritoneal mast cells did not report such effects by oestrogenic agents (Vliagoftis et al., 
1992), more recent study by Zaitsu et al (2007) demonstrated similar mast cell activating 
action on the rat mast cell line, RBL-2H3 cells. In Zaitsu's study, 17/5-estradiol alone 
was able to induce partial release of the preformed, granular protein /^-hexosaminidase 
and the newly synthesized leukotriene C4 from RBL-2H3 cells. A gradual increase of 
mediator release (3-15%) was observed, dose-dependently from to lO'^^M, while 
further increase of estradiol concentrations from lO'川 to lO'^M, gradually reduced the 
inducing effect. In another study using female Wistar rat RPMCs, dose-independent low 
level of histamine release of 2-3% was also observed with 17/5-estradiol from lO'^ ^M to 
lO'^M. However, the author did not consider this as a significant effect (Cocchiara et al., 
1990). 
Low level of mediators release by oestrogens suggested that oestrogens may act as pro-
inflammatory agents in some instances. Activated bladder mast cells were observed in 
patients of interstitial cystitis (IC) and they were more responsive than normal cells 
when challenged by anti-IgE and carbachol (Sant et al” 2007; Spanos et aL, 1996). 
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Premenopausal women are more susceptible to inflammatory diseases such as interstitial 
cystitis (IC) than postmenopausal women and their symptoms often worsen 
premenstmally (Pang et al., 1995). The possible explanations can be that levels of 
oestrogens play a role in modulating mast cell activation and patients of this disorder 
were more sensitive to the mast cell activation by oestrogens. Bladder mast cells from 
women with IC were found to exhibit increased expression of high affinity oestrogen 
receptors (Sant et al., 2007)and increased mast cell activation in IC patients was detected 
with increased inflammatory mediators e.g. histamine, arachidonic acid metabolites, 
tumor necrosis factor in urine premenstmally (Erickson). However, the exact mechanism 
on how oestrogens stimulate mast cell activation in these patients still remains unclear. 
One of the suggested effects of oestrogens on mast cells was related to calcium influx. 
Indeed, intracellular calcium was increased within the first 2.5 minutes after oestrogenic 
stimulation of rat mast cells (Zaitsu et al., 2007) and the reaction strictly required 
extracellular Ca^^ presence in the media. Therefore, blocking one or more types of Ca^^ 
channels on mast cells might improve the worsen situation of IC during premenstrual 
stage. 
Another result obtained from our study indicated that significant inhibitory effect on 
anti-IgE induced histamine release was observed with 17/5-estradioL Again, male, 
female, sham-operated and ovariectomized RPMCs were studied and the results 
obtained were similar. Inhibitory effect on anti-IgE induced histamine release was 
observed in all cases with maximum percentage inhibition around 50% in all four groups. 
Therefore, we can conclude that gender differences as well as endogenous oestrogen 
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level are not factors affecting the oestrogenic effect on RPMCs. However, our results 
were different from those described in previous studies (Cocchiara et al., 1990; 
Vliagoftis et al., 1992). In the study of Vliagoftis, it was claimed that no significant 
changes in anti-IgE induced histamine release with 17/5-estradiol added to the RPMCs, 
while in Cocchiara study, anti-IgE induced histamine release was enhanced by oestrogen. 
Another study using mast cell line RBL 2H3 as their source, also indicated simultaneous 
exposure to oestrogen and allergen cross-linking of surface IgE has a synergistic effect 
on the release of histamine (Zaitsu et al., 2007). However, when we further analyze their 
data, we found out that the claimed enhancement was simply straight summative values 
of histamine release induced independently by oestrogen and anti-IgE. In fact a slight 
suppression of IgE receptor mediated histamine release by 17/5-estradiol was observed in 
some cases. The apparent discrepancies may be explained by the possible heterogeneity 
of oestrogen receptor isoform expression between different strains of animals. In the 
study of (Cocchiara et al., 1990)，Wistar RPMCs were able to have enhanced mediators 
released after pre-incubation with oestradiol, while Sprague-Dawley rats were used in 
the present study. Besides, drug pre-incubation times between studies were different. In 
the previous studies, mast cells were often pre-incubated with oestrogen for 90 minutes 
to hours while our study focused on studying effects of oestrogen within 10 minutes. At 
the beginning of our study, we have investigated the effects of different pre-incubation 
period of oestrogenic agents with male, female, sham-operated and ovariectomized 
RPMCs. The results showed that both the low histamine release being stimulated by 
oestrogenic agents alone and the inhibitory effects of ITjS-estradiol on anti-IgE induced 
histamine release remained the same following 0, 10 and 30 minutes of pre-incubation. 
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This suggested that the oestrogenic effects observed on RPMCs were almost 
instantaneous and a possible non-genomic pathway may take part. Further study on the 
non-genomic effects of oestrogenic agents will be carried out in the next chapter. 
As SERMs are popularly employed in oestrogen hormone replacement therapy, effects 
of tamoxifen and raloxifene on anti-IgE induced histamine release on RPMCs was also 
studied. The inhibitory effect of anti-IgE induced histamine release was also observed by 
tamoxifen and raloxifene. However, raloxifene at concentrations above 10'^M exhibited 
an enhancing effect which was not observed by either 17/5-estradiol or tamoxifen. In the 
results using tamoxifen as the testing drug, there was no significant difference between 
male and female, indicating that gender was not a factor affecting the results. However, 
when compared to the ovariectomized rats, a higher percentage inhibition was observed. 
The differences maybe due to endogenous oestrogen level present. For raloxifene, it also 
demonstrated a different degree of inhibitory effect in female rats when compared to 
other groups of rats. In female rats, raloxifene of lO'^M already demonstrated enhancing 
effect while in other cases enhancing effect was observed when concentration was above 
lO'^M. When comparing the degree of inhibition of histamine release from RPMCs, 
17/5-estradiol was shown to have a higher potency on inhibiting mast cell degranulation 
than the two SERMs, demonstrating that RPMCs are more susceptible to 17/5-estradiol 
than tamoxifen and raloxifene (Fig 3.33— 3.34). 
To further delineate oestrogen receptor subtypes responsible for the oestrogenic effects, 
specific oestrogen receptor agonists, PPT (ER-a agonist) and DPN (ER-/5 agonist), were 
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employed in our study. When compared to the results obtained by 17/3-estradiol, it was 
interesting that both of them were unable to show significant anti-IgE induced histamine 
inhibition, except at very high dose (lO'^M), in male RPMCs. In contrast, significant 
percentage inhibition was observed at most of the drug concentrations tested in both 
female and ovariectomized rats. The discrepancies observed might be due to different 
levels of oestrogen receptor subtypes expression between male and females. The 
expression of oestrogen receptor subtypes will be discussed in the later chapter. 
However, the differences in results by 17/5-estradiol and selective oestrogen receptor 
agonists suggested that 17/3-estradiol action on RPMCs may not be entirely dependent 
on classic receptor. The inhibitory degree by various oestrogen receptor agonists and 
SERMs were compared. The potencies of inhibitory effect were compared as 17(3-
estradiol > raloxifene, tamoxifen > DPN, PPT (Fig. 3.33 — 3.34). 
Ovariectomized (OVX) rats were employed as a study model to mimic the 
postmenopausal stage. Results showed no significant differences between the 
ovariectomized and sham-operated rats, indicating that in our study model, oestrogen 
agonists and SERMs did not produce different actions on RPMCs of different stages. 
The oestrogens and SERMs still exert inhibition of histamine release of RPMCs even 
though the circulating levels of endogenous oestrogen maintained in normal female SD 
rats are higher than in the ovariectomized animals. From our results, we cannot explain 
the incident of cardio- and neuro-inflammatory protection by oestrogen and SERMs 
observed between pre- and postmenopausal women. However in another study, OVX 
rats were more sensitive to carrageenan-induced inflammation than the sham-operated 
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group, and 17/5-estradiol and raloxifene can attenuate the induced inflammation 
(Esposito et al., 2005). 
Roles of mast cells in osteoporosis had been studied for almost 50 years, of which 
histamine, the most abundant product in mast cells, played an important role in the bone 
turnover regulation. The bone remodeling is mediated by the balanced activities of 
osteoclasts, which absorb existing bone, and osteoblasts, which form new bone. In many 
postmenopausal women, the extent of bone resorption exceeds that of formation, 
resulting in osteoporosis and increased fracture risk (Crisp et al., 1986). Application of 
histamine blocker to mouse models could reduce osteoclast activation as well as 
numbers of osteoclasts by HI and H2 blockade. In postmenopausal women, blocking of 
H2 receptors with cimetidine was associated with lower bone loss as compared with 
controls (Chiappetta et al., 2006). In addition, a deletion of histamine-synthesizing 
enzyme gene, histidine decarboxylase, increases bone formation and protects against 
ovariectomy-induced bone loss in mice (Fitzpatrick et al” 2003). In general, oestrogens 
are believed to have a bone protection effect since postmenopausal women are often 
having a higher risk in developing osteoporosis. In our study, 17/5-estradiol，SERMs and 
oestrogen receptor agonists were shown to have inhibitory effect on histamine release 
from activated mast cells. These results demonstrated that oestrogenic effect on RPMCs 
can reduce histamine release which in turns lower bone loss and encourage bone 
protection, of which, raloxifene is the only currently available SERM for the treatment 
and prevention of postmenopausal osteoporosis (Gianni et al., 2004). 
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Results from our study showed many differences when compared to previous studies 
(Cocchiara et al., 1990; Vliagoftis et al., 1992; Zaitsu et al., 2007). The discrepancies 
may be due to the solvent used by previous investigators. They used Tyrode solution for 
dissolving the 17/3-estradiol but we found that it is impossible to obtain a clear solution 
as this drug is highly insoluble in water. In addition, they used DMSO and ethanol as 
solvent for other drugs. In our preliminary study, DMSO and ethanol alone were shown 
having ability to inhibit mast cell degranulation. Therefore, in our study we control the 
DMSO concentration (<0.01%) at a level that has no significant effect on histamine 
release. However in their study, the DMSO concentration was much higher than 0.01%. 
Furthermore, ways of sensitizing tested animals were different. Previous studies 
employed passive sensitization, meaning RPMCs were sensitized with IgE for 1 hour 
before starting the histamine release experiment. Some of the studies even employed 
unsensitized RPMCs for studying the immunological pathway. In our study, Sprague-
Dawley rats were being sensitized by ovalbumin at least 4 weeks prior to the histamine 
release experiments. 
In our study, the findings that oestrogens can stimulate a low level histamine release 
alone and suppress anti-IgE induced histamine release from activated mast cells 
demonstrated that oestrogens produce dual actions on RPMCs, which can be correlated 
to IC and osteoporosis correspondingly. However, the differences in pre- and 
postmenopausal stages were not observed. 
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Figure 3.1 Effects of oestrogen receptor agonists on histamine release from RPMCs of 
male SD rats. Cells were incubated with oestrogen agonists for 20 minutes and the 
corresponding histamine release was measured. Results are given as the means 士 SEM 
for n 二 5. 
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Figure 3.2 Effects of oestrogen receptor agonists on histamine release from RPMCs of 
female SD rats. Cells were incubated with oestrogen agonists for 20 minutes and the 
corresponding histamine release was measured. Results are given as the means 士 SEM 
for n = 5. 
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Figure 3.3 Effects of oestrogen receptor agonists on histamine release from RPMCs of 
male SD rats in different time courses. Cells were incubated with 17/5-estradiol for 0，10 
and 30 minutes respectively and the corresponding histamine release was measured. 
Results are given as the means 士 SEM for n = 7.There are no significant differences 
amongst different incubation time. 
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Figure 3.4 Effects of oestrogen receptor agonists on histamine release from RPMCs of 
sham-operated SD rats. Cells were incubated with oestrogen agonists for 20 minutes and 
the corresponding histamine release was measured. Results are given as the means 士 
S E M f o r n = 3. 
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Figure 3.5 Effects of oestrogen receptor agonists on histamine release from RPMCs of 
ovariectomized SD rats. Cells were incubated with oestrogen agonists for 20 minutes 
and the corresponding histamine release was measured. Results are given as the means 土 
SEM for n - 3 . 
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Figure 3.6 Effect of oestrogen on anti-IgE-induced histamine release from RPMCs. 
RPMCs from male SD rats was challenged with anti-IgE without pre-incubation with 
17/3-estradioL Anti-IgE induced histamine release from ITjS-estradiol treated (•) and 
untreated (*) RPMCs are shown. Results are given as the means 土 SEM for n 二 3. 
Asterisks indicate statistically significant (p<0.05 at least) different levels of histamine 
release when compared to that induced by anti-IgE alone. 
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Figure 3.7 Effect of oestrogen on anti-IgE-induced histamine release from RPMCs. 
RPMCs from male SD rats were pre-incubated with 17/5-estradiol for 10 minutes before 
challenge with anti-IgE. Anti-IgE induced histamine release from 17|3-estradiol treated 
( • ) and untreated (*) RPMCs are shown. Results are given as the means 士 SEM for n = 
11. Asterisks indicate statistically significant (p<0.05 at least) different levels of 
histamine release when compared to that induced by anti-IgE alone. 
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Figure 3.8 Effect of oestrogen on anti-IgE-induced histamine release from RPMCs. 
RPMCs from male SD rats were pre-incubated with 1 TjS-estradiol for 30 minutes before 
challenge with anti-IgE. Anti-IgE induced histamine release from 17/3-estradiol treated 
(•) and untreated (*) RPMCs are shown. Results are given as the means 士 SEM for n = 
3. Asterisks indicate statistically significant (p<0.05 at least) different levels of 
histamine release when compared to that induced by anti-IgE alone. 
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Figure 3.9 Effect of oestrogen on anti-IgE-induced histamine release from RPMCs. 
RPMCs from female SD rats were pre-incubated with 17/3-estradiol for 10 minutes 
before challenge with anti-IgE. Anti-IgE induced histamine release from 17jS-estradiol 
treated ( • ) and untreated (*) RPMCs are shown. Results are given as the means 土 SEM 
for n = 8. Asterisks indicate statistically significant (p<0.05 at least) different levels of 
histamine release when compared to that induced by anti-IgE alone. 
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Figure 3.10 Percentage inhibition of anti-IgE induced histamine release from RPMCs. 
Inhibitory percentage of anti-IgE induced histamine release from male RPMCs and 
female RPMCs by ITjS-estradiol were compared. Results are given as the means 士 SEM 
for n = 8-11. 
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Figure 3.11 Effect of oestrogen on anti-IgE-induced histamine release from RPMCs. 
RPMCs from sham-operated and ovariectomized female SD rats were pre-incubated 
with 17/5-estradiol for 10 minutes before challenge with anti-IgE. Results are given as 
the means 士 SEM for n = 6. Asterisks indicate statistically significant (p<0.05 at least) 
different levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 3.12 Percentage inhibition of anti-IgE induced histamine release from RPMCs. 
Inhibitory percentage of anti-IgE induced histamine release from sham-operated RPMCs 
and ovariectomized RPMCs by 17/5-estradiol were compared. Results are given as the 
means 士 SEM for n = 6. 
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Figure 3.13 Effect of selective oestrogen receptor modulator on anti-IgE-induced 
histamine release from RPMCs. RPMCs from male SD rats were pre-incubated with 
tamoxifen for 10 minutes before challenge with anti-IgE. Anti-IgE induced histamine 
release from tamoxifen treated ( • ) and untreated (*) RPMCs are shown. Results are 
given as the means 士 SEM for n = 3. Asterisks indicate statistically significant (p<0.05 
at least) different levels of histamine release when compared to that induced by anti-IgE 
alone. 
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Figure 3.14 Effect of selective oestrogen receptor modulator on anti-IgE-induced 
histamine release from RPMCs. RPMCs from female SD rats were pre-incubated with 
tamoxifen for 10 minutes before challenge with anti-IgE. Anti-IgE induced histamine 
release from tamoxifen treated ( • ) and untreated (*) RPMCs are shown. Results are 
given as the means 士 SEM for n 二 5. Asterisks indicate statistically significant (p<0.05 
at least) different levels of histamine release when compared to that induced by anti-IgE 
alone. 
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Figure 3.15 Percentage inhibition of anti-IgE induced histamine release from RPMCs. 
Inhibitory percentage of anti-IgE induced histamine release from male RPMCs and 
female RPMCs by tamoxifen were compared. Results are given as the means 士 SEM for 
n 二 3—5. 
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Figure 3.16 Effect of selective oestrogen receptor modulator on anti-IgE-induced 
histamine release from RPMCs. RPMCs from sham-operated and ovariectomized SD 
rats were pre-incubated with tamoxifen for 10 minutes before challenge with anti-IgE. 
Results are given as the means 士 SEM for n = 5. Asterisks indicate statistically 
significant (p<0.05 at least) different levels of histamine release when compared to that 
induced by anti-IgE alone. 
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Figure 3.17 Percentage inhibition of anti-IgE induced histamine release from RPMCs. 
Inhibitory percentage of anti-IgE induced histamine release from sham-operated RPMCs 
and ovariectomized RPMCs by tamoxifen were compared. Results are given as the 
means 士 SEM for n = 4. 
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Figure 3.18 Effect of selective oestrogen receptor modulator on anti-IgE-induced 
histamine release from RPMCs. RPMCs from male SD rats were pre-incubated with 
raloxifene for 10 minutes before challenge with anti-IgE. Anti-IgE induced histamine 
release from raloxifene treated ( • ) and untreated (*) RPMCs are shown. Results are 
given as the means 土 SEM for n = 11. Asterisks indicate statistically significant (p<0.05 
at least) different levels of histamine release when compared to that induced by anti-IgE 
alone. 
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Figure 3.19 Effect of selective oestrogen receptor modulator on anti-IgE-induced 
histamine release from RPMCs. RPMCs from female SD rats were pre-incubated with 
raloxifene for 10 minutes before challenge with anti-IgE. Anti-IgE histamine release 
from raloxifene treated ( • ) and untreated (*) RPMCs are shown. Results are given as the 
means 士 SEM for n = 4. Asterisks indicate statistically significant (p<0.05 at least) 
different levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 3.20 Percentage inhibition of anti-IgE induced histamine release from RPMCs. 
Inhibitory percentage of anti-IgE induced histamine release from male RPMCs and 
female RPMCs by raloxifene were compared. Results are given as the means 士 SEM for 
n = 4~ l l . 
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Figure 3.21 Effect of selective oestrogen receptor modulator on anti-IgE-induced 
histamine release from RPMCs. RPMCs from sham-operated and ovariectomized SD 
rats were pre-incubated with raloxifene for 10 minutes before challenge with anti-IgE. 
Results are given as the means 士 SEM for n = 3. Asterisks indicate statistically 
significant (p<0.05 at least) different levels of histamine release when compared to that 
induced by anti-IgE alone. 
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Figure 3.22 Percentage inhibition of anti-IgE induced histamine release from RPMCs of 
sham-operated and ovariectomized rats by raloxifene. Results are given as the means 士 
SEM for n = 3. Asterisks indicate statistically significant (p<0.05 at least) levels of 
histamine release between sham-operated and ovariectomized rats. 
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Figure 3.23 Effect of specific oestrogen receptor a agonist on anti-IgE-induced 
histamine release from RPMCs. RPMCs from male SD rats were pre-incubated with 
PPT for 10 minutes before challenge with anti-IgE. Anti-IgE induced histamine release 
from PPT treated ( • ) and untreated (*) RPMCs are shown. Results are given as the 
means 士 SEM for n = 6. Asterisks indicate statistically significant (p<0.05 at least) 
different levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 3.24 Effect of specific oestrogen receptor a agonist on anti-IgE-induced 
histamine release from RPMCs. RPMCs from female SD rats were pre-incubated with 
PPT for 10 minutes before challenge with anti-IgE. Anti-IgE induced histamine release 
from PPT treated ( • ) and untreated (*) RPMCs are shown. Results are given as the 
means 士 SEM for n = 5. Asterisks indicate statistically significant (p<0.05 at least) 
different levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 3.25 Percentage inhibition of anti-IgE induced histamine release from RPMCs. 
Inhibitory percentage of anti-IgE induced histamine release from male RPMCs and 
female RPMCs by PPT were compared. Results are given as the means 士 SEM for n 二 5. 
There is no significant difference between sexes. 
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Figure 3.26 Effect of specific oestrogen receptor a agonist on anti-IgE-induced 
histamine release from RPMCs. RPMCs from sham-operated and ovariectomized SD 
rats were pre-incubated with PPT for 10 minutes before challenge with anti-IgE. Results 
are given as the means 士 SEM for n = 3. Asterisks indicate statistically significant 
(p<0.05 at least) different levels of histamine release when compared to that induced by 
anti-IgE alone. 
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Figure 3.27 Percentage inhibition of anti-IgE induced histamine release from RPMCs. 
Inhibitory percentage of anti-IgE induced histamine release from sham-operated RPMCs 
and ovariectomized RPMCs by PPT were compared. Results are given as the means 士 
SEM for n = 3.There is no significant difference between operated rats. 
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Figure 3.28 Effect of specific oestrogen receptor (3 agonist on anti-IgE-induced 
histamine release from RPMCs. RPMCs from male SD rats were pre-incubated with 
DPN for 10 minutes before challenge with anti-IgE. Anti-IgE induced histamine release 
from DPN treated ( • ) and untreated (*) RPMCs are shown. Results are given as the 
means 士 SEM for n = 4. Asterisks indicate statistically significant (p<0.05 at least) 
different levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 3.29 Effect of specific oestrogen receptor agonist on anti-IgE-induced 
histamine release from RPMCs. RPMCs from female SD rats were pre-incubated with 
DPN for 10 minutes before challenge with anti-IgE. Anti-IgE induced histamine release 
from DPN treated ( • ) and untreated (*) RPMCs are shown. Results are given as the 
means 士 SEM for n = 3. Asterisks indicate statistically significant (p<0.05 at least) 
different levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 3.30 Percentage inhibition of anti-IgE induced histamine release from RPMCs. 
Inhibitory percentage of anti-IgE induced histamine release from male RPMCs and 
female RPMCs by PPT were compared. Results are given as the means 士 SEM for n = 
3-4. There is no significant difference between sexes. 
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Figure 3.31 Effect of specific oestrogen receptor agonist on anti-IgE-induced 
histamine release from RPMCs. RPMCs from sham-operated and ovariectomized SD 
rats were pre-incubated with DPN for 10 minutes before challenge with anti-IgE. Results 
are given as the means 士 SEM for n = 4. Asterisks indicate statistically significant 
(p<0.05 at least) different levels of histamine release when compared to that induced by 
anti-IgE alone. 
106 
Chapter 3 ： Effect of Oestrogens on Immunological Induced Histamine Release 
From Rat peritoneal Mast Cells 
75-1 
- I F - S H A M 
•••〇VX 
^ 5 0 -
125-_ 
0 -
I 1 I I 1 1 1 -9 -8 -7 -6 -5 
[DPN] (log M) 
Figure 3.32 Percentage inhibition of anti-IgE induced histamine release from RPMCs. 
Inhibitory percentage of anti-IgE induced histamine release from sham-operated RPMCs 
and ovariectomized RPMCs by DPN were compared. Results are given as the means 士 
SEM for n = 4.There is no significant difference between operated rats. 
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Figure 3.33 Compared values of different oestrogen receptor agonists and SERMs on 
inhibition of anti-IgE induced histamine release from male RPMCs. Results are given as 
the means 士 SEM for n = 3 — 8. 
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Figure 3.34 Compared values of different oestrogen receptor agonists and SERMs on 
inhibition of anti-IgE induced histamine release from female RPMCs. Results are given 
as the means 士 SEM for n = 3 — 8. 
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4. Elucidating the Mechanism Underlying the Effects of 
Oestrogens on Rat Peritoneal Mast Cells 
4.1 Introduction 
Conventionally, oestrogens like other steroid hormones, act as nuclear transcription 
factors by modulating target genes through complex interactions with coactivators, 
corepressors, histone modifying enzymes and proteins comprising basal transcriptional 
machinery (Manavathi et al., 2006). In addition to the classical pathway mediated by the 
intracellular receptors, oestrogen can exert rapid, non-genomic steroid actions. The non-
genomic signaling has the following features which are different from the classical 
genomic one: responses often take place in a few seconds or minutes and are insensitive 
to inhibitors of mRNA and protein synthesis. 
The non-genomic signaling of oestrogens involves a series of events depending on the 
cell type. Increases of intracellular second messengers (e.g. calcium and cAMP) were 
observed in granulosa cells (Morley et al., 1992), hippocampal neurons (Wu et al., 
2005), T cells (Benten et al., 1998) and cervical cancer cells (Lobaton et al., 2005). 
Rapid induction of nitric oxide release by modulation of nitric oxide synthase was 
detected in endothelial cells (Goetz et al., 1999; Kim et al., 1999). Activation ofMAPK 
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signaling pathway was reported in breast cancer, endothelial and bone (Bjomstrom et al., 
2005) whereas, activation of phosphoinositol 3-kinase signaling pathway was identified 
in liver cells (Bjomstrom et al., 2005). 
Amongst all non-genomic effects induced by oestrogens, modulations of calcium 
movement in both inter- and intracellular ways are related to mast cell activation. Mast 
cells activation involves calcium movement from intracellular stores as well as calcium 
influx and several data published had suggested that 1 TjS-estradiol can modulate calcium 
movement in immunologically- and non-immunologically activated mast cells 
(Vliagoftis et al., 1992; Zaitsu et al., 2007). Tamoxifen is also shown to have ability in 
antagonizing the calcium movement by 17/5-estradiol in the presence of extracellular 
calcium in buffer. This suggests that 17/5-estradiol affects calcium influx rather than 
intracellular calcium released from calcium stores. This type of oestrogen receptor 
stimulation has been shown to induce rapid cellular responses through G-protein 
activation, which can induce various signaling pathways including calcium influx, 
modulation of mitogen-activated protein kinases and adenyl cyclase (Zaitsu et al” 2007). 
Mast cell activation can be carried out through immunological and non-immunological 
ways. They are of two different mechanisms to activate mast cells, of which, 
immunological activation depends on aggregation of IgE molecules on mast cell surface, 
while non-immunological activation depends on direct activation of pertussis toxin 
(PTX)-sensitive G proteins. Anti-IgE is used as mast cell secretagogue in activating mast 
cells immunologically while compound 48/80 and substance P belong to basic 
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compounds and peptides which stimulate mast cells non-immunologically (Columbo et 
al” 1996). By using rat peritoneal mast cells (RPMCs) as study tool to investigate the 
relationship between oestrogens and mast cells，results have shown that different 
activation pathways can alter responses of oestrogens on RPMCs. In the study of 
Cocchiara (1990), it was reported that both substance P and compound 48/80 induced 
histamine release were not affected by oestrogen; while in the study of Vliagoftis (1992), 
the results obtained were just opposite. The importance of extracellular Ca^^ for 
oestrogenic effects on RPMCs hence remains controversial. 
The presence of non-genomic pathway suggested that membrane oestrogen receptors 
(mER) exist. The current debate over mERs focused on their nature and properties. 
Recently, scientists suggested existence of ERs distinct from classic ones. Experiments 
involved classic receptors knock-out animal could still exhibit oestrogen induced 
extracellular regulated kinase (ERK) phosphorylation (Singh et al” 2000) and rapid 
neural Fos response (Dominguez-Salazar et al., 2006) in brain. Pre-incubation with 
oestrogen receptor antagonist, which was supposed to block both ER-a and ER-/3, did 
not mask over the oestrogen induced ion current. In neuronal cells, which lacks 
functional ER, oestrogen can still activate mitogen-activated protein kinase (MAPK) 
signaling and augment the release of amyloid /5-precursor protein (Manthey et al., 2001). 
Some studies suggested that the mER expressed was identical with at least one of the 
intracellular oestrogen receptors because they shared similar complementary DNA 
(Razandi et al., 1999). ER-a subtype was detected on the clonal rat prolactinoma cell 
surface which was capable of being stimulated by oestrogens and phytoestrogens and 
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caused induce rapid activation of ERKs and Ca channel opening (Watson et al., 2005). 
There was also an oestrogen receptor-like protein, distinct from ER-o; concentrated in 
the lipid rafts detected in osteoblasts (Heberden et al,, 2006). However, some suggested 
different forms of mERs discovered on different cell surfaces. G protein-coupled 
oestrogen receptor was suggested on mast cell surface (Mizota et al, 2006) and other 
oestrogen receptor subtypes were identified on macrophage surface (Benten et al., 1998). 
Others suggested that non-genomic actions of oestrogens and xenoestrogens by binding 
to a plasma membrane receptor were unrelated to either ER- a or oestrogen receptor (3 
(ER-/3) (Nadal et al., 2000). 
Expressions of ERs on mast cells were reported in different tissues. There are more than 
95% of mast cells expressing ERs in nasal polyps of patients with nasal obstruction 
(Shirasaki et al., 2004). Expression of oestrogen receptors by mast cells alone but not 
lymphocytes, macrophages or other immune cells in human upper airways was 
recognized by immunohistochemistry method, however the ER subtypes were not 
identified (Zhao et al., 2001). High affinity ERs were also located on bladder mast cells 
of patients with interstitial cystitis by immunofluorescence staining but the ER subtypes 
were not characterized in this study (Pang et aL, 1996). Recently, mRNA expression of 
ER-a was expressed on rat basophilic leukemia cell line (RBL-2H3), human mast cell 
line (HMC-1) and bone marrow-derived mast cells (BMMC) but not ER-jS, suggesting 
that ER-a may be the possible ER responsible for the oestrogenic effects on mast cells 
(Zaitsu et al., 2007). 
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In order to further characterize the effects demonstrated by oestrogen receptor agonists 
and SERMs in the previous chapter, we first investigated if the effects were mediated 
through membrane binding sites by studying the activities of the membrane 
impermeable BSA-conjugated estradiol. Secondly, we investigated the activities of ER 
antagonist on the mast cell modulating actions of oestrogenic agents. Thirdly, inhibitors 
of mRNA and protein synthesis such as the transcription blocker, actinomycin-D，and 
the translation blocker, cycloheximide, were used to elucidate the involvement of 
genomic pathways. Fourthly, the ER subtypes from male, female, sham-operated and 
ovariectomized rat RPMCs were identified by mRNA expression detected with RT-PCR. 
Finally, oestrogenic effects on RPMCs of compound 48/80 and substance P induced 
histamine release was also studied, since modulation of external calcium influx had been 
suggested to play a role in rapid non-genomic actions of oestrogens 
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4.2 Materials and Methods 
The methods and materials employed are as described in chapter 2. Anti-IgE 
concentration of 1/1000 was used for stimulation of the purified RPMCs which induced 
an average of 20%-30% histamine release. Similar levels of histamine release were 
induced by compound 48/80 at 0.1|ag/ml and Substance P at 10|j.M (Cocchiara et al, 
1990; Vliagoftis et al, 1992; Zaitsu et al, 2007). All results are corrected for spontaneous 
release in buffer alone, while secretagogues induced histamine releases in the presence 
of oestrogens are corrected also for the oestrogen induced release. RT-PCR was 
performed as described in chapter 2. RNA and cDNA samples extracted were stored at -
70°C and -20°C, respectively before further usage. 
For the studies on the effects of ER antagonists as well as the transcription and 
translation blockers, only RPMCs from male rats were used, as the oestrogenic actions 
in all four groups of rats were similar in the previous chapter. 
The highest drug concentrations of various drugs tested in the study varied according to 
their solubility in solvents. When DMSO was used as the solvent to prepare stock 
solutions of drugs, the DMSO concentration in the highest drug concentration test must 
be <0.01%, at which DMSO does not produce any effects on mediator release, as 
confirmed by parallel control tests containing such DMSO dilutions performed with the 
actual experiments. 
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Results were analyzed, using paired 广-test, for statistical significance by comparing 
secretagogues induced histamine release in the presence of oestrogen to control release 
induced by secretagogues alone. Two way ANOVA was employed when comparing the 
effects of oestrogenic agents between two different groups of animals. Differences were 
considered significant when/?<0.05. 
4.3 Results 
The overall spontaneous release of histamine from purified RPMCs incubated with 
buffer alone did not exceed 20%. A general increase in spontaneous release was 
observed with incubation time. Oestrogen receptor agonists induce an approximately 5% 
to 10% histamine release from RPMCs without any dose-dependent tendency, while 
oestrogen antagonists did not induce any significant release. All data are presented as 
percentage of histamine release after correction for the spontaneous release. Anti-IgE 
induced histamine release in the presence of various oestrogen receptor agonists were 
further corrected for the drug induced histamine release. The suppression of histamine 
release by test drugs was converted into inhibition percentage according to the 
calculation formula stated in chapter 2. 
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4.3.1 The Involvement of Membrane Oestrogen Receptors 
4.3.1.1 Effects of Membrane Impermeable Oestrogen on Anti-IgE mediated 
Histamine Release from RPMCs 
In our experiments, the membrane impermeable BSA-estradiol was able to initiate by 
itself up to 7.3 士 0.8o/o and 7.0 士 l.io/o of histamine release from RPMCs of male and 
female animals respectively (Fig. 4.1). When tested against anti-IgE induced histamine 
release, significant inhibition was observed at concentration as low as lO'^^M in the male 
rats with anti-IgE induced histamine release reduced from 21.0 士 1.5o/o to 10.8 士 2.2o/o 
(Fig. 4.2). Although there does not seem to be any dose dependency, the reduction 
induced by lO'^M BSA-estradiol was not as significant as those produced by the lower 
concentrations. In mast cells isolated from female rats, significant inhibition was only 
'n c 
observed at 10" M and 10' M without any apparent dose dependent manner. A reduction 
of anti-IgE induced histamine release from 31.2 士 3.1 o/o to 21.5 士 3.2o/o was observed in 
female RPMC at lO'^M (Fig. 4.3). The highest inhibition value obtained in male is 56.2 
士 5.70/0 while for female is 31.6 士 5.3o/o (Fig 4.4). 
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4.3.2 Effects of Oestrogen Receptor Antagonists on the Modulating Actions of 
Oestrogen Receptor Agonists and SERMs on RPMC of Male Rats 
4.3.2.1 Effects on Oestrogen Receptor Agonists and SERMs Induced Low Level 
Histamine Release from RPMCs 
Histamine release induced by 17|(5-estradiol, BSA-conjugated estradiol, oestrogen 
receptor agonists and SERMs were not significantly suppressed after pre-incubation 
with the non-specific oestrogen receptor antagonist ICI 182780 and the ER-o: specific 
antagonist MPP dihydrochloride at lO'^M and lO'^M (Fig. 4.5 and 4.6). Oestrogenic 
agents were able to continue inducing around 10% histamine release subsequent to 
preincubation with the antagonists. These low levels of histamine release were all 
significantly higher than the spontaneous histamine release in buffer alone. 
4.3.2.2 Effects on the Inhibitory Actions on Anti-IgE Mediated Histamine Release 
from RPMCs 
Non-selective oestrogen receptor antagonist, ICI 182780，and ER-a specific antagonist, 
MPP dihydrochloride, of lO'^M and lO'^M concentration were applied in order to 
counteract the inhibitory effect of 17i8-estradiol, tamoxifen, raloxifene, DPN, PPT and 
BSA-conjugated estradiol on anti-IgE induced histamine release from RPMCs (Zaitsu et 
al., 2007). 
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17j(3-estradiol of lO'^M to lO'^M concentration significantly suppressed anti-IgE induced 
histamine release from male RPMCs, with the highest percentage inhibition of 57.2 士 
10.3% at lO'^M. As the RPMCs were pre-incubated with the ICI 182780 before 
challenged by 1 TjS-estradiol and anti-IgE, the inhibitory effect was reversed. The level of 
histamine release was restored back to the level as if no 17j3-estradiol was added to the 
anti-IgE induced histamine release. The reversal effect by ICI 182780 was observed in 
both concentrations (Fig. 4.7). Similar result was also observed with the ER-a specific 
antagonist, MPP dihydrochloride. The maximum percentage inhibition produced by 1 
estradiol was 53.5 士 6.6o/o and the inhibitory action was reversed by both concentrations 
of antagonists (Fig. 4.8). 
Tamoxifen of lO'^M to lO'^M concentration was able to provide an inhibitory effect on 
anti-IgE induced histamine release, with the highest percentage inhibition of 39.6 ± 
12.5% at ICI 182780 and MPP dihydrochloride of lO'^M and lO'^M were pre-
incubated with RPMCs before addition of tamoxifen. Results indicated that both ICI 
182780 and MPP dihydrochloride were able to reverse the inhibitory effect of anti-IgE 
induced histamine release (Fig. 4.9 and Fig. 4.10). 
Raloxifene of lO-'^ M and IQ-^M significantly suppressed anti-IgE induced histamine 
release, with the highest percentage inhibition of 69.0 士 22.5o/o at lO'^M. When the 
RPMCs were pre-incubated with ICI 182780 before addition of raloxifene and anti-IgE, 
the inhibitory action of raloxifene on anti-IgE induced histamine release was alleviated. 
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However, the enhancing effect of raloxifene on anti-IgE induced histamine release at 10" 
^M was not significantly reversed by ICI 182780 pre-incubation (Fig. 4.11). ER-a 
specific antagonist, MPP dihydrochloride, was employed to study its effect on raloxifene 
induced inhibitory effect. Similar to ICI 182780, it was able to reverse the inhibitory 
effect by raloxifene at concentration 10'^M and lO'^M. However, MPP dihydrochloride 
of lO'^M was able to reverse the enhancing effect of raloxifene at 10 M，which result 
was different from the one by ICI 182780 (Fig. 4.12). 
Oestrogen receptor-a agonist, PPT, was employed and induced a maximum of 87.2 士 
1.7% inhibition of anti-IgE induced histamine release at lO'^M concentration of PPT. 
When ICI 182780 of lO'^M and were preincubated with male RPMCs, the 
significant inhibition was not reversed (Fig. 4.13). However, the inhibitory effect was 
reversed by both and lO'^M of the ER-a specific antagonist MPP dihydrochloride 
(Fig. 4.14). 
Oestrogen receptor-jS agonist, DPN, was found to significantly suppress anti-IgE 
induced histamine release at lO'^M concentration, giving a percentage inhibitory value 
of 44.5 ± 9.2%. Preincubation of male RPMCs with lO'^M and lO'^M ICI 182780 before 
the addition of DPN and anti-IgE, the antagonist reversed the level of histamine release 
back to that induced by anti-IgE alone (Fig. 4.15). MPP dihydrochloride of lO'^M and 
lO'^M were pre-incubated with RPMCs, again, the inhibitory trend by lO'^M of DPN 
was reversed, however, the reversal effect was not statistically significant (Fig. 4.16). 
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The membrane impermeable BSA-conjugated estradiol significantly suppressed anti-IgE 
induced histamine release at lO'^M and lO'^M, with highest percentage inhibitory value 
of 51.6 士 26.50/0 at lO'^M of BSA-estradiol. ICI 182780 was able to reverse this 
significant inhibition at both lO'^M and (Fig. 4.17). MPP dihydrochloride of 10' 
^M was not able to reverse the inhibitory effect by BSA-conjugated estradiol on anti-IgE 
induced histamine release. As the antagonist concentration increased to lO'^M, the 
reversal effect by MPP dihydrochloride was observed. The histamine release with BSA-
conjugated estradiol was reversed back to the histamine release level induced by anti-
IgE alone (Fig. 4.18). 
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4.3.3 Effects of Transcription and Translation Blockers on the Inhibition Effects of 
Oestrogen Receptor Agonists and SERMs on RPMC of Male Rats 
One of the features of non-genomic effect by oestrogen is being insensitive to 
transcription and translation blockers. In the following experiments, actinomycin-D 
(transcription blocker) and cycloheximide (translation blocker) were employed to study 
if the inhibitory effect by 17P-estradiol as well as the biphasic effect by raloxifene on 
anti-IgE induced histamine release were abolished after the pre-incubation with these 
blockers. 
17/3-estradiol of dose ranged from lO'^^M to lO'^M was able to significantly suppress 
anti-IgE induced histamine release. When the male RPMCs were pre-incubated with 10" 
^M actinomycin-D (Horwitz and McGuire, 1978) and lO'^M cycloheximide (Fischer et 
al., 2006) respectively for 30 minutes, the statistically significant inhibitory effect of 
histamine release induced by 17/5-estradiol was not affected (Fig. 4.19 and Fig. 4.20). 
This indicated that the inhibitory effect by 17j(3-estradiol on male RPMCs did not involve 
both transcription and translation process. 
Raloxifene exhibited inhibitory effect at concentration lO'^M to lO'^M, while enhancing 
effect at lO'^M on anti-IgE induced histamine release. When the male RPMCs were pr-
incubated with lO'^M actinomycin-D and lO'^M cycloheximide respectively for 30 
minutes, the statistically significant inhibitory effect as well as the enhancing effect by 
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raloxifene were not affected (Fig. 4.21 and Fig. 4.22). This indicated that transcription 
and translation processes were not involved. 
4.3.4 Identification of Oestrogen Receptor Subtypes on RPMCs 
4.3.4.1 Molecular Expression of Oestrogen Receptor Subtypes on RPMCs 
Fragment of oestrogen receptor a (ER-a) mRNA (344-base pair) was detected after PCR 
amplification (Fig. 4.24) while fragment of oestrogen receptor /5 (ER-/3) mRNA (262-
base pair) was not (Fig. 4.25). Housekeeping GAPDH gene was amplified and used as 
normalized reference gene for the agarose gel electrophoresis (Fig. 4.23). Results 
obtained were consistent and reproducible in three different trials. 
4.3.5 Effects of Oestrogenic Agents on activation of RPMCs by Non-Immunological 
Stimuli 
4.3.5.1 Effects of Oestrogen on Compound 48/80 Mediated Histamine Release from 
RPMCs 
When tested at concentrations which were able to significantly suppress anti-IgE 
induced histamine release, only the highest tested concentration (lO'^M) of 17/5-estradiol 
displayed statistically significant inhibition (Fig. 4.26) on compound 48/80 induced 
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histamine release from mast cells of male rats. Histamine release was reduced from 18.3 
士 1.50/0 to 11.2 士 1.90/0 at lO'^M drug concentration. In the case of normal female 
RPMCs, histamine release was also significantly suppressed from 19.8 土 2.6o/o to 9.5 士 
1.7% at lO'^M (Fig. 4.27). The maximum percentage inhibitions induced by lO'^M of 
17i(5-estradiol on male and female RPMCs were 39.4 士 7.5o/o and 52.6 士 4.3o/o 
respectively (Fig. 4.28). However, in sham-operated and ovariectomized SD rats, 
significant inhibitory effect was observed at all the tested concentrations (Fig. 4.29). The 
basic secretagogue induced histamine release from sham-operated and ovariectomized 
rats was suppressed by 1 TjS-estradiol from 27.4 士 1.3o/o to 14.8 士 2.2o/o at lO'^M and 25.2 
土 1.30/0 to 12.5 土 4.40/0 at IO'iIm respectively. When converted to percentage inhibitory 
values, the highest inhibition obtained from sham-operated and ovariectomized rats were 
50.4 士 5.90/0 and 37.8 士 1 l.Oo/o respectively (Fig. 4.30). 
4.3.5.2 Effects of Selective Oestrogen Receptor Modulators on Compound 48/80 
Mediated Histamine Release from RPMCs 
Tamoxifen displayed significant inhibitory effects in both sexes (Fig. 4.31 and Fig. 4.32). 
Compound 48/80 induced histamine release from both male and female RPMCs were 
suppressed from 22.8 士 2.5o/o to 8.7 士 1.8o/o and 24.9 士 4.4o/o to 14.8 士 1.2o/o at lO'^M of 
tamoxifen respectively and the corresponding maximum inhibition were 78.2 士 4.0o/o 
and 38.1 士 7.6o/o in male and female respectively (Fig. 4.33). As the concentration 
increased, the inhibitory effects were diminished. 
124 
Chapter 4: Elucidating the Mechanism Underlying the Effects of Oestrogens 
On Rat Peritoneal Mast Cells 
Raloxifene demonstrated significant inhibitory effect on compound 48/80 challenged 
RPMCs at doses below lO'^M from male and female RPMCs (Fig. 4.34 and Fig. 4.35). 
The compound 48/80 induced release was significantly suppressed from 12.3 士 2.3o/o to 
4.8 士 IJo/o in female RPMCs and 31.9 士 1.3o/o to 23.2 士 3.6o/o in male RPMCs at 
of raloxifene with the maximum percentage inhibition of 57.1 士 5.0o/o in male and 81.2 士 
7.1% in female RPMCs (Fig. 4.36). 
4.3.5.3 Effects of Membrane Impermeable Oestrogen on Compound 48/80 
Mediated Histamine Release from RPMCs 
Compound 48/80 induced histamine release on RPMCs of both male and female SD rats 
were significantly inhibited by BSA-conjugated estradiol. The compound 48/80 induced 
histamine release was reduced from 22.8 士 1.6o/o to 15.7 士 2.2o/o at lO'^M and 19.9 士 
2.0% to 13.9 士 1.8% at lO'^M respectively (Fig. 4.37 — 4.38). The highest inhibition 
observed in male is 23.7 士 9.TA while in female is 30.7 士 2.5o/o (Fig 4.39). 
4.3.5.4 Effects of Oestrogen on Substance P Mediated Histamine Release from 
RPMCs 
17|3-estradiol was able to produce significant inhibitory effect on histamine release from 
substance P challenged RPMCs from to 10'^  M in both male and female samples 
(Fig. 4.40 and Fig. 4.41). Substance P induced histamine release was suppressed from 
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33.4 士 2.10/0 to 19.2 士 1.40/0 in male and 30.7 士 2.4o/o to 19.4 士 2.9o/o in female at 
concentration. The maximum histamine release inhibition values (47.8 士 8.2o/o and 36.9 
土 8.2o/o) were obtained in male and female rats (Fig. 4.42). Similar significant inhibitory 
effects were observed in sham-operated and ovariectomized SD samples (Fig. 4.43). 
Histamine release was reduced from 24.4 士 2.5o/o to 13.7 士 1.9o/o and 24.7 士 1.4o/o to 
14.8 士 1.70/0 at lO'^^M in sham-operated and ovariectomized RPMCs. The highest 
inhibition acquired were 69.1 士 3.8o/o and 80.0 土 3.9o/o (Fig 4.44). There was no 
significant difference between these two operated groups. 
4.3.5.5 Effects of Selective Oestrogen Receptor Modulators on Substance P 
Mediated Histamine Release from RPMCs 
Effect of ist generation SERM, tamoxifen, was studied with neuropeptide substance P 
induced histamine release from RPMCs. Only results at the highest tested dose (lO'^M) 
demonstrated significant inhibitory effect by tamoxifen in both sexes (Fig. 4.45 and Fig. 
4.46). A maximum of 34.9 士 7.6o/o and 50.9 士 3.1o/o percentage of inhibition were 
observed in male and female respectively (Fig. 4.47). 
Raloxifene, the generation SERM, only displayed significant inhibitory effect at low 
raloxifene concentrations (Fig. 4.48 and Fig. 4.49) and the inhibitory potency reduced 
with increasing concentrations. The substance P induced histamine release was 
suppressed by lO'^M of raloxifene from 26.5 土 2.6% to 15.7 士 2.2o/o in male RPMCs, 
126 
Chapter 4: Elucidating the Mechanism Underlying the Effects of Oestrogens 
On Rat Peritoneal Mast Cells 
and from 29.0 士 2.8o/o to 16.4 士 2.2o/o in females. A slight enhancing effect of histamine 
release was observed, however results were not statistically significant. (Fig. 4.50). 
4.3.5.6 Effects of Membrane Impermeable Oestrogen on Substance P Mediated 
Histamine Release from RPMCs 
Neuropeptide-induced histamine release was inhibited by BSA-conjugated estradiol in a 
dose-independent manner. Substance P at lO'^^M induced histamine release from male 
RPMCs was reduced from 30.4 士 1.3o/o to 17.9 士 2.2o/o and 29.1 士 0.4o/o to 17.7 土 0.9o/o 
in female RPMCs (Fig. 4.51 and Fig. 4.52). The highest inhibition observed in male and 
female was 40.9 士 7.2o/o and 39.0 土 3.8o/o respectively (Fig. 4.53). 
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4.4 Discussion 
In this chapter, we have investigated several aspects of oestrogenic effects on RPMCs. 
We have tried to identify if the oestrogenic effects observed in the last chapter is a non-
genomic one and to characterize which oestrogen receptor subtypes may be involved. 
We have also looked into the oestrogenic effects on non-immunologically stimulated 
RPMCs which would address indirectly the importance of external calcium influx to the 
oestrogenic effects on activated mast cells. 
We found that BSA-conjugated estradiol applied to unstimulated RPMCs for 20 minutes 
was able to induce a significant histamine release of about 5% — 10%. This degree of 
histamine release was similar to those induced by oestrogen receptor agonist and 
SERMs in the previous chapter. Besides this low level histamine release on unstimulated 
RPMCs, BSA-conjugated estradiol also demonstrated an inhibitory action on stimulated 
RPMCs. According to our results, significant inhibiting effect was observed, as the one 
demonstrated by various oestrogen receptor agonists and SERMs in the previous chapter. 
The observed difference in inhibitory percentage by BSA-conjugated estradiol between 
genders was probably due to the deviation of the corresponding release in controls (Fig. 
4.4). The deviation of release from control results exaggerated the inhibition percentage 
after mathematic calculation. BSA-conjugated estradiol consists of 32 moles of estradiol 
with 1 mole of BSA. The bulky hydrophilic BSA prevents the drug from entering the 
cell while at the same time allows the oestradiol molecules to exert effects on cell 
surface. BSA-conjugated estradiol has been extensively used in other research areas for 
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identifying the oestrogenic effects through the possible membrane oestrogen receptors. 
Studies reported that BSA-conjugated estradiol, but not unconjugated estradiol, was able 
to activate extracellular signal-regulated protein kinases (ERKl and ERK2) in the SK-N-
SH neuroblastoma cell line (Stevis et al., 1999). Therefore, from the results we obtained, 
we suggested that both stimulatory and inhibitory oestrogenic effects on RPMCs were 
mediated via the mast cell surfaces. 
In order to further characterize if the effects observed are mediated through receptors 
related to conventional oestrogen receptors, the oestrogen receptor antagonists, ICI 
182780 and MPP dihydrochloride, were used to antagonize the inhibitory effect induced 
by various oestrogen receptor agonists and SERMs. MPP dihydrochloride has a higher 
potency than ICI 182780 towards ER-a and it displays more than 200 fold selectivity for 
ER-Q: over ER-/5, which unlike ICI 182780，has no specificity on either ER subtypes. 
According to the results, both non-selective and selective antagonists were able to 
antagonize the inhibitory effect, however, the stimulatory effect (5% - 10%) remains 
unchanged. The insensitivity of the stimulatory effect to the ER antagonists suggests that 
it may not be mediated through receptors related to conventional ERs. It had been 
suggested non-genomic calcium influx by oestrogens binding at a plasma membrane 
receptor which was unrelated to ER-o: and ER-/5 in pancreatic 13 cells (Nadal et al., 2000). 
The specific antagonizing effect exhibited by MPP dihydrochloride on ER-a reversed 
the inhibition, showing that ER-a subtype plays a role in the inhibitory effect of mast 
cell degranulation. Previous study has claimed that ER-a is the prominent ER subtypes 
responsible for acute effects of oestrogens on mast cells (Zaitsu et al., 2007). Besides, 
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anti-inflammatory role by ER-o: was also observed in other systems including reduction 
of cytokine IL-6，IL-4, IL-2, IL-10, TNF-a and TNF-7 by 17/5-estradiol and selective 
ER-a ligand in experimental autoimmune encephalomyelitis model (Elloso et al., 2005; 
Polanczyk et al., 2003) and inhibition of brain inflammatory process by inhibiting 
microglia activation (Vegeto et al., 2003). Since commercially available ER-/5 
antagonists were not available at the time of the current study, we could not study the 
participation of ER-/5 in our antagonist study. However, ER-/3 had been suggested to 
play an anti-inflammatory role by suppressing NF-/cB activity in human aorta 
endothelial cells (Chadwick et al., 2005). In the inflammatory bowel disease model, 
using HLA-B27 transgenic rat, the induced intestinal inflammation and chronic diarrhea 
were reduced by ER-/3 specific agonists ERB-041 and WAY-202196. The effect through 
ER-/3 was even blocked by ICI 182780, providing strong evidence that the effect was 
ER-dependent (Hamish et al., 2004). At the time of writing, a relatively selective ER-/3 
antagonist, PHTPP, has become available and it would be useful to include this in future 
studies to better characterize the membrane ER subtype. 
To further investigate if the oestrogenic effects on RPMCs were mediated through non-
genomic pathway, DNA transcription and translation blockers were employed. The 
inhibitory effects displayed by oestrogen receptor agonists and SERMs were insensitive 
to both transcription and translation blockers, which further confirmed that these effects 
on RPMCs do not involve any genomic transcription and translation processes that often 
take hours to complete. The presence of membrane ER-o; however had been questioned 
as some studies suggested that it would be impossible for nucleus ER-a to travel from 
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intracellular to the membrane surface as the classical receptor do not contain stretches of 
hydrophobic transmembrane domains, having no intrinsic kinase or phosphatase activity, 
and lack myristoylation sites (Manavathi et al., 2006). On the other hand, there are 
suggestions that several post-translation modifications of ER-o: could allow them to be 
localized on the cell surface (Razandi et al” 2003). Furthermore, expression of ER-a 
mRNA was observed in rat basophilic leukemia cell line (RBL-3H2), human mast cell 
(HMC-1) and primary cultures of bone marrow-derived mast cells (BMMC) of mice 
(Zaitsu et al., 2007). Also, majority of interstitial cells from human nasal mucosa of 
patients having nasal obstruction were ER-a expression dominant mast cells (Shirasaki 
et al., 2004). In our study, ER-o: mRNA was identified by reverse transcriptase PCR in 
RPMCs of all groups of animals while ER-/3 was not detected as reported in previous 
studies. 
As some studies suggested the ability of modulation of calcium influx by oestrogens 
through receptors similar to ER-a (Watson et al., 2005; Zaitsu et al., 2007), we would 
like to investigate if oestrogenic agents produced different actions on histamine release 
induced by basic secretagogues which mast cell activating pathways do not dependent 
upon extracellular calcium. In the last chapter, oestrogenic agents generally inhibited the 
anti-IgE induced histamine release which depended on the presence of extracellular 
calcium. Here, results showed that compound 48/80 and substance P induced histamine 
release from rat RPMCs were also significantly suppressed by 17/5-estradiol, tamoxifen 
and raloxifene. Although both of the agents activate mast cells through activation of G-
protein, the degree of percentage inhibition of histamine release by them were different. 
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1 TjS-estradiol inhibited compound 48/80 induced histamine release only at lO'^M in male 
while in female the inhibition started from lO'^M. While in the case of substance P, 
histamine release was suppressed from lO'^^M of 17/3-estradiol in both genders of rats. 
g 
Also, compound 48/80 induced histamine release was suppressed by tamoxifen at 10' M 
in both sexes while substance P induced histamine release was only suppressed at the 
highest concentration (lO'^M) of tamoxifen in both sexes. Raloxifene also significantly 
suppressed compound 48/80 induced histamine release at concentration of lO'^M — 10' 
^M in both sexes, however, only lO'^M of raloxifene was able to significantly suppress 
substance P induced histamine release. Although a general inhibitory tendency by 
raloxifene was observed, significant differences were not detected, an increase of n 
numbers may help to give a better significant result. Results from sham-operated and 
ovariectomized rats also showed no differences between them, demonstrating that even 
though the endogenous oestrogen level was different, the external oestrogenic effects on 
non-immunologically induced histamine release were not affected. 
When the results obtained via calcium influx dependent anti-IgE pathway and calcium 
influx insensitive basic secretagogues pathway were compared, both 17p-estradiol and 
tamoxifen elicit similar degree of inhibition in all cases. However, the raloxifene action 
was different. Raloxifene significantly enhanced anti-IgE induced histamine release at 
lO'^M, but no statistically significant enhancing effect by raloxifene was observed in the 
case of basic secretagogues induced histamine release. 
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Our results obtained were again different from those reported by the others. In both 
Vliagoftis and Cocchiara studies, they demonstrated different oestrogenic effects in 
immunological and non-immunological pathways (Cocchiara et al., 1990; Vliagoftis et 
al., 1992). Although their results contradicted to each other, none of them showed 
inhibitory effect by 17j3-estradiol. However, in our study, inhibitory effect was observed 
by 17/5-estradiol and SERMs. There were no differences in the inhibitory effects of the 
oestrogenic agents on either immunologically and non-immunologically induced mast 
cell activation. When the inhibitory potency amongst different oestrogen receptor 
agonists and SERMs are compared, they shared similar inhibitory potency in both 
compound 48/80 and substance P induced histamine release (Fig. 4.53 — 4.56). In non-
immunological mast cell activation pathway, cationic secretagogue, compound 48/80, 
and substance P stimulate a putative G-protein which transiently increases intracellular 
Ca2+ concentration through the G-protein mediated activation of phospholipase C (PLC) 
and thus induce mast cell degranulation (Lorenz et al,, 1998). Since same inhibitory 
effects by oestrogenic agents were observed in both immunological and non-
immunological pathways, the involvement of Ca influx regulation was not an 
important mechanism in explaining the suppression of mediator release from activated 
mast cells. 
In summary, the current investigation has demonstrated that oestrogenic agents can 
produce a weak stimulatory effect on unstimulated mast cells and a significant inhibitory 
action on activated mast cells. Both actions of oestrogenic agents have rapid onset and 
are not affected by gender or endogenous oestrogen levels. The involvement of 
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membrane sites of action and non-genomic mechanisms are suggested. While the 
inhibitory action is mediated through membrane receptors related to conventional ER, 
the stimulatory action is mediated through ER unrelated membrane sites. The inhibitory 
actions are not related to regulation of calcium influx as both anti-IgE and basic 
secretagogue induced releases are similarly affected. Further works are required to 
delineate the underlying molecular mechanisms of these modulating actions of 
oestrogenic agents on mast cell activities. 
In relation to the stimulatory action, the most published rapid effect induced by 17/?-
estradiol is an increase in intracellular calcium [Ca� .]” The way to increase [Ca^^Ji may 
be due to an influx of extracellular Ca^ "^  or a mobilization of Ca^^ from intracellular Ca^^ 
stores, of which, both ways of increasing had been reported in different cells. 
17i3-estradiol was shown to induce Ca^^ influx via L-type calcium channels in neuronal 
cells (Wu et al,, 2005). On the other hand, mobilization of Ca^^ from intracellular stores 
was also reported in breast cancer cell line (Improta-Brears et al, 1999)，endothelial 
cells (Goetz et al, 1999; Kim et al., 1999) and granulosa cells (Morley et al., 1992). 
However, it was shown that cytosolic free Ca^^ was raised in T cells via both Ca^ "^  influx 
and mobilization of Ca^^ from intracellular stores (Benten et al., 1998). Measurement of 
[Ca^^Ji by the use of Fura-2 loaded RPMCs can help us to elucidate if the stimulatory 
effect of oestrogenic agents involves increasing on Ca^^ levels in RPMCs. Also, we can 
make use of calcium blockers, both inter and intra ones, to check which calcium 
modulation pathway is regulated by oestrogens. If we can show this Ca^^ modulating 
action by oestrogen can work on mast cells, then we can explain the release of histamine 
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release by oestrogenic agents in our study. Besides, by interacting with 
phosphatidylinositol 3-kinase (PI3K), 17/5-estradiol and raloxifene activated protein 
kinase Akt and increased endothelial nitric oxide (NO) synthase activity in endothelial 
cells (Simoncini et al., 2000; Simoncini et al., 2003). Activation of mitogen activated 
protein kinase (MAPK) signaling was also reported in neuronal and non-neuronal cells 
(Manthey et al., 2001). Nevertheless, since activation of these pathways were shown in 
other cell systems, detailed study of these pathways in mast cells by 17-estradiol should 
be carried out as PI3K and MAPK pathways were important for mast cell degranulation. 
Although inhibitory actions by IT/^-estradiol were observed in other inflammatory 
models, most effects were not as rapid as those observed in our cases. In the model of 
inflammatory bowel disease, BMMCs derived from femurs and tibias of mice were 
cultured with oestrogen for 3 days ahead of the /^-hexosaminidase release assay. Result 
indicated a 50% reduction in mast cell degranulation as assessed by /^-hexosaminidase 
release. The pre-incubation time with oestrogen was long enough for oestrogen to 
suppress inflammatory cytokines TNF-o; IL-6 and IL-13 expressions (Hamish et al., 
2004). However in our study, rapid non-genomic pathway that took place indicated that 
direct inhibition of inflammatory gene expression was not involved. In Ghisletti study 
(2005), it had demonstrated that pre-incubation of 17/5-estradiol (lO'^M) with 
macrophages for 10 minutes was able to block lipopolysaccharide-induced intracellular 
localization of transcription factor nuclear factor kB (NF-/cB) via ER-(X This action was 
insensitive to genomic blocker and was shown to act through a rapid non-genomic 
pathway. This indicated that 17/3-estradiol had the ability to modulate cytosolic 
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molecules through membrane receptors, but the modulation of which signaling pathways 
remained unclear. The secondary messenger cAMP was also shown to be elevated 
acutely by oestrogenic agents within 10 minutes. It was shown that in several cell 
systems (e.g. neuronal cells, MCF-7 breast cancer cells and kidney cells), 17p-estradiol, 
genistein as well as BSA-conjugated estradiol were able to activate cAMP production 
via activation of adenylyl cyclase (Filardo et al., 2007; Gu et al” 1996; Liu et al., 2006; 
Zivadinovic et al., 2005). Since the elevation of cAMP levels in mast cells has been 
shown to inhibit mast cell degranulation (Sullivan et al., 1975a; Tasaka, 1994), it is of 
interest in the future to study the effect of oestrogenic agents on cAMP production in 
mast cells. 
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Figure 4.1 Effects of membrane impermeable oestrogen on histamine release from 
RPMCs. RPMCs from male and female SD rats were pre-incubated with BSA-
conjugated estradiol (BSA-E2) for 20 minutes and the corresponding histamine release 
was then measured. Results are given as the means 士 SEM for n = 4. 
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Figure 4.2 Effect of membrane impermeable oestrogen on anti-IgE-induced histamine 
release from RPMCs. RPMCs from male SD rats were pre-incubated with BSA-
conjugated estradiol (BSA-E2) for 10 minutes before challenge with anti-IgE. Results 
are given as the means 士 SEM for n = 4. Asterisks indicate statistically significant 
(p<0.05 at least) different levels of histamine release when compared to that induced by 
anti-IgE alone. 
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Figure 4.3 Effect of membrane impermeable oestrogen on anti-IgE-induced histamine 
release from RPMCs. RPMCs from female SD rats were pre-incubated with BSA-
conjugated estradiol (BSA-E2) for 10 minutes before challenge with anti-IgE. Results 
are given as the means 士 SEM for n = 4. Asterisks indicate statistically significant 
(p<0.05 at least) different levels of histamine release when compared to that induced by 
anti-IgE alone. 
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Figure 4.4 Percentage inhibition of anti-IgE induced histamine release from RPMCs. 
Inhibitory percentage of histamine release by BSA-conjugated estradiol from male 
RPMCs and female RPMCs were compared by two-way ANOVA and were significantly 
different. Results are given as the means 士 SEM for n = 4-6. 
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Figure 4.5 Effects of ICI 182780 on histamine release induced by oestrogen receptor 
agonists and SERMs. RPMCs from male SD rats were pre-incubated with 10'^  M ICI 
182780 for 30 minutes and the corresponding histamine release was then measured. 
Results are given as the means 士 SEM for n = 3 - 5. 
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Figure 4.6 Effects of MPP dihydrochloride on histamine release induced by oestrogen 
receptor agonists and SERMs. RPMCs from male SD rats were pre-incubated with 10" 
^M MPP dihydrochloride for 30 minutes and the corresponding histamine release was 
then measured. Results are given as the means 士 SEM for n = 3 — 5. 
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Figure 4.7 Effect of non-selective ER antagonist, ICI 182780 (ICI), on anti-IgE-induced 
histamine release from RPMCs. RPMCs from male SD rats were incubated with ICI for 
10 minutes prior to the 10 minutes incubation with 17p-estradiol (17P-E2). The cell 
mixture was lastly challenged by anti-IgE for further 10 minutes. Results are given as 
the means 士 SEM for n = 4. Asterisks indicate statistically significant (p<0.05 at least) 
different levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 4.8 Effect of ER-a antagonist, MPP dihydrochloride (MPP), on anti-IgE-induced 
histamine release from RPMCs. RPMCs from male SD rats were incubated with MPP 
for 10 minutes prior to the 10 minutes incubation with 17P-estradiol (17P-E2). The cell 
mixture was lastly challenged by anti-IgE for further 10 minutes. Results are given as 
the means 士 SEM for n = 5. Asterisks indicate statistically significant (p<0.05 at least) 
different levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 4.9 Effect of non-selective ER antagonist, ICI 182780 (ICI), on anti-IgE-induced 
histamine release from RPMCs. RPMCs from male SD rats were incubated with ICI for 
10 minutes prior to the 10 minutes incubation with tamoxifen (Ta). The cell mixture was 
lastly challenged by anti-IgE for further 10 minutes. Results are given as the means 土 
SEM for n = 5. Asterisks indicate statistically significant (p<0.05 at least) different 
levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 4.10 Effect of ER-a antagonist, MPP dihydrochloride (MPP), on anti-IgE-
induced histamine release from RPMCs. RPMCs from male SD rats were incubated with 
MPP for 10 minutes prior to the 10 minutes incubation with tamoxifen (Ta). The cell 
mixture was lastly challenged by anti-IgE for further 10 minutes. Results are given as 
the means 士 SEM for n = 5. Asterisks indicate statistically significant (p<0.05 at least) 
different levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 4.11 Effect of non-selective ER antagonist, ICI 182780 (ICI), on anti-IgE-
induced histamine release from RPMCs. RPMCs from male SD rats were incubated with 
ICI for 10 minutes prior to the 10 minutes incubation with raloxifene (Ra). The cell 
mixture was lastly challenged by anti-IgE for further 10 minutes. Results are given as 
the means 士 SEM for n = 3. Asterisks indicate statistically significant (p<0.05 at least) 
different levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 4 .12 Effect o f ER-o: antagonist, MPP dihydrochloride (MPP), on anti-IgE-
induced histamine release from RPMCs. RPMCs from male S D rats were incubated with 
MPP for 10 minutes prior to the 10 minutes incubation with raloxifene (Ra). The cell 
mixture was lastly challenged by anti-IgE for further 10 minutes. Results are given as 
the means 士 SEM for n = 4. Asterisks indicate statistically significant (p<0.05 at least) 
different levels o f histamine release when compared to that induced by anti-IgE alone. 
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Figure 4.13 Effect o f non-selective ER antagonist, ICI 182780 (ICI), on anti-IgE-
induced histamine release from RPMCs. RPMCs from male S D rats were incubated with 
ICI for 10 minutes prior to the 10 minutes incubation with PPT. The cell mixture was 
lastly challenged b y anti-IgE for further 10 minutes. Results are given as the means 士 
SEM for n = 3. Asterisks indicate statistically significant (p<0.05 at least) different 
levels o f histamine release when compared to that induced by anti-IgE alone. 
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Figure 4.14 Effect of ER-a antagonist, MPP dihydrochloride (MPP), on anti-IgE-
induced histamine release from RPMCs. RPMCs from male SD rats were incubated with 
MPP for 10 minutes prior to the 10 minutes incubation with PPT. The cell mixture was 
lastly challenged by anti-IgE for further 10 minutes. Results are given as the means 士 
SEM for n = 3. Asterisks indicate statistically significant (p<0.05 at least) different 
levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 4.15 Effect of non-selective ER antagonist, ICI 182780 (ICI), on anti-IgE-
induced histamine release from RPMCs. RPMCs from male SD rats were incubated with 
ICI for 10 minutes prior to the 10 minutes incubation with DPN. The cell mixture was 
lastly challenged by anti-IgE for further 10 minutes. Results are given as the means 士 
SEM for n = 4. Asterisks indicate statistically significant (p<0.05 at least) different 
levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 4.16 Effect of ER-O! antagonist, MPP dihydrochloride (MPP), on anti-IgE-
induced histamine release from RPMCs. RPMCs from male SD rats were incubated with 
MPP for 10 minutes prior to the 10 minutes incubation with DPN. The cell mixture was 
lastly challenged by anti-IgE for further 10 minutes. Results are given as the means 士 
SEM for n = 3. Asterisks indicate statistically significant (p<0.05 at least) different 
levels of histamine release when compared to that induced by anti-IgE alone. 
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Figure 4.17 Effect of non-selective ER antagonist, ICI 182780 (ICI), on anti-IgE-
induced histamine release from RPMCs. RPMCs from male SD rats were incubated with 
ICI for 10 minutes prior to the 10 minutes incubation with BSA-conjugated estradiol 
(BSA-E2). The cell mixture was lastly challenged by anti-IgE for further 10 minutes. 
Results are given as the means 士 SEM for n = 3. Asterisks indicate statistically 
significant (p<0.05 at least) different levels of histamine release when compared to that 
induced by anti-IgE alone. 
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Figure 4.18 Effect of ER-a antagonist, MPP dihydrochloride (MPP), on anti-IgE-
induced histamine release from RPMCs. RPMCs from male SD rats were incubated with 
MPP for 10 minutes prior to the 10 minutes incubation with BSA-conjugated estradiol 
(BSA-E2). The cell mixture was lastly challenged by anti-IgE for further 10 minutes. 
Results are given as the means 士 SEM for n = 3. Asterisks indicate statistically 
significant (p<0.05 at least) different levels of histamine release when compared to that 
induced by anti-IgE alone. 
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Figure 4.19 Effect of DNA transcription blocker on anti-IgE-induced histamine release 
from RPMCs. RPMCs from male SD rats were pre-incubated with lO'^M DNA 
transcription blocker, actinomycin D (ActD), for 10 minutes prior to the 10 minutes 
incubation of 17/5-estradiol (17/5-E2). Lastly, treated RPMCs were challenged with anti-
IgE for further 10 minutes. Results are given as the means 土 SEM for n 二 6. Asterisks 
indicate statistically significant (p<0.05 at least) difference in levels of histamine release 
between anti-IgE alone (*) and \7I3-E2 together with anti-IgE ( • ). There are no 
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Figure 4.20 Effect of DNA translation blocker on anti-IgE-induced histamine release 
from RPMCs. RPMCs from male SD rats were pre-incubated with DNA 
translation blocker, cycloheximide (cyclohex), for 10 minutes prior to the 10 minutes 
incubation of 1 TjS-estradiol (17/3-F2). Lastly, treated RPMCs were challenged with anti-
IgE for further 10 minutes. Results are given as the means 土 SEM for n = 5. Asterisks 
indicate statistically significant (p<0.05 at least) difference in levels of histamine release 
between anti-IgE alone (*) and 17/5-E2 together with anti-IgE ( • ). There are no 
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Figure 4.21 Effect of DNA transcription blocker on anti-IgE-induced histamine release 
from RPMCs. RPMCs from male SD rats were pre-incubated with lO'^M DNA 
transcription blocker, actinomycin D (ActD), for 10 minutes prior to the 10 minutes 
incubation of selective oestrogen receptor modulator, Raloxifene (Ra). Lastly, treated 
RPMCs were challenged with anti-IgE for further 10 minutes. Results are given as the 
means 土 SEM for n = 7. Asterisks indicate statistically significant (p<0.05 at least) 
difference in levels of histamine release between anti-IgE alone (*) and Ra together with 
anti-IgE ( • ). There are no statistical significant differences between results with and 
without DNA transcription blocker. 
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Figure 4.22 Effect of DNA translation blocker on anti-IgE-induced histamine release 
from RPMCs. RPMCs from male SD rats were pre-incubated with lO'^M DNA 
translation blocker, cycloheximide (cyclohex), for 10 minutes prior to the 10 minutes 
incubation of selective oestrogen receptor modulator, Raloxifene (Ra). Lastly, treated 
RPMCs were challenged with anti-IgE for further 10 minutes. Results are given as the 
means 土 SEM for n = 5. Asterisks indicate statistically significant (p<0.05 at least) 
difference in levels of histamine release between anti-IgE alone (*) and Ra together with 
anti-IgE ( • ). There are no statistical significant differences between results with and 
without DNA transcription blocker. 
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Figure 4.23 Expression of control gene (GAPDH) mRNA from different samples. 
From Left to Right: Lane 1: lOObp ladder marker; Lane 2: Positive control (rat lung 
tissue); Lane 3: Negative control (no primers added during PCR amplification); Lane 4: 
Male rat peritoneal mast cells; Lane 5: Female rat peritoneal mast cells; Lane 6: 
Ovariectomized female rat peritoneal mast cells 
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Figure 4.24 Expression of oestrogen receptor-a (ER-a) mRNA from different samples. 
From Left to Right: Lane 1: lOObp ladder marker; Lane 2: Positive control (rat lung 
tissue); Lane 3: Negative control (no primers added during PCR amplification); Lane 4: 
Male rat peritoneal mast cells; Lane 5: Female rat peritoneal mast cells; Lane 6: 
Ovariectomized female rat peritoneal mast cells 
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Figure 4.25 Expression of oestrogen receptor-p (ER-p) mRNA from different samples. 
From Left to Right: Lane 1: lOObp ladder marker; Lane 2: Positive control (rat lung 
tissue); Lane 3: Negative control (no primers added during PCR amplification); Lane 4: 
Male rat peritoneal mast cells; Lane 5: Female rat peritoneal mast cells; Lane 6: 
Ovariectomized female rat peritoneal mast cells. 
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Figure 4.26 Effect of oestrogen on basic secretagogue-induced histamine release from 
RPMCs. RPMCs from male SD rats were pre-incubated with 17/5-estradiol for 10 
minutes before challenge with compound 48/80. Compound 48/80 induced histamine 
release from 1 TjS-estradiol treated ( • ) and untreated (*) RPMCs are shown. Results are 
given as the means 士 SEM for n = 5. Asterisks indicate statistically significant (p<0.05 
at least) different levels of histamine release when compared to that induced by 
compound 48/80 alone. 
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Figure 4.27 Effect of oestrogen on basic secretagogue-induced histamine release from 
RPMCs. RPMCs from female SD rats were pre-incubated with ITjS-estradiol for 10 
minutes before challenge with compound 48/80. Compound 48/80 induced histamine 
release from 17/5-estradiol treated (•) and untreated (*) RPMCs are shown. Results are 
given as the means 士 SEM for n 二 4. Asterisks indicate statistically significant (p<0.05 
at least) different levels of histamine release when compared to that induced by 
compound 48/80 alone. 
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Figure 4.28 Percentage inhibition of compound 48/80 induced histamine release from 
RPMCs. Inhibitory percentage of compound 48/80 induced histamine release from male 
RPMCs and female RPMCs by 17/5-estradiol were compared. Results are given as the 
means 士 SEM for n 二 4-5. There is no significant different between sexes. 
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Figure 4.29 Effect of oestrogen on basic secretagogue-induced histamine release from 
RPMCs. RPMCs from sham operated and ovariectomized female SD rats were pre-
incubated with 17/5-estradiol for 10 minutes before challenge with compound 48/80. 
Results are given as the means 士 SEM for n = 4. Asterisks indicate statistically 
significant (p<0.05 at least) different levels of histamine release when compared to that 
induced by compound 48/80 alone. 
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Figure 4.30 Percentage inhibition of compound 48/80 induced histamine release from 
RPMCs. Inhibitory percentage of compound 48/80 induced histamine release from 
sham-operated RPMCs and ovariectomized RPMCs by 1 TjS-estradiol were compared. 
Results are given as the means 士 SEM for n = 3.There is no significant difference 
between operated rats. 
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Figure 4.31 Effect of selective oestrogen receptor modulator on basic secretagogue-
induced histamine release from RPMCs. RPMCs from male SD rats were pre-incubated 
with tamoxifen for 10 minutes before challenge with compound 48/80. Compound 48/80 
induced histamine release from tamoxifen treated ( • ) and untreated (*) RPMCs are 
shown. Results are given as the means 土 SEM for n = 3. Asterisks indicate statistically 
significant (p<0.05 at least) different levels of histamine release when compared to that 
induced by compound 48/80 alone. 
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Figure 4.32 Effect of selective oestrogen receptor modulator on basic secretagogue-
induced histamine release from RPMCs. RPMCs from female SD rats were pre-
incubated with tamoxifen for 10 minutes before challenge with compound 48/80. 
Compound 48/80 induced histamine release from tamoxifen treated ( • ) and untreated (*) 
RPMCs are shown. Results are given as the means 士 SEM for n 二 3. Asterisks indicate 
statistically significant (p<0.05 at least) different levels of histamine release when 
compared to that induced by compound 48/80 alone. 
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Figure 4.33 Percentage inhibition of compound 48/80 induced histamine release from 
RPMCs. Inhibitory percentage of compound 48/80 induced histamine release from male 
RPMCs and female RPMCs by tamoxifen were compared. Results are given as the 
means 土 SEM for n = 3. There is no significant different between sexes. 
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Figure 4.34 Effect of selective oestrogen receptor modulator on basic secretagogue-
induced histamine release from RPMCs. RPMCs from male SD rats were pre-incubated 
with raloxifene for 10 minutes before challenge with compound 48/80. Compound 48/80 
induced histamine release from raloxifene treated ( • ) and untreated (*) RPMCs are 
shown. Results are given as the means 士 SEM for n = 5. Asterisks indicate statistically 
significant (p<0.05 at least) different levels of histamine release when compared to that 
induced by compound 48/80 alone. 
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Figure 4.35 Effect of selective oestrogen receptor modulator on basic secretagogue-
induced histamine release from RPMCs. RPMCs from female SD rats were pre-
incubated with raloxifene for 10 minutes before challenge with compound 48/80. 
Compound 48/80 induced histamine release from raloxifene treated ( • ) and untreated (*) 
RPMCs are shown. Results are given as the means 土 SEM for n = 4. Asterisks indicate 
statistically significant (p<0.05 at least) different levels of histamine release when 
compared to that induced by compound 48/80 alone. 
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Figure 4.36 Percentage inhibition of compound 48/80 induced histamine release from 
RPMCs. Inhibitory percentage of compound 48/80 induced histamine release from male 
RPMCs and female RPMCs by raloxifene were compared. Results are given as the 
means 土 SEM for n = 4-5. There is no significant different between sexes� 
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Figure 4.37 Effect of membrane impermeable oestrogen on basic secretagogue-induced 
histamine release from RPMCs. RPMCs from male SD rats were pre-incubated with 
BSA-conjugated estradiol (BSA-E2) for 10 minutes before challenge with compound 
48/80. Compound 48/80 induced histamine release from BSA-E2 treated ( • ) and 
untreated (*) RPMCs are shown. Results are given as the means 土 SEM for n = 3. 
Asterisks indicate statistically significant (p<0.05 at least) different levels of histamine 
release when compared to that induced by compound 48/80 alone. 
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Figure 4.38 Effect of membrane impermeable oestrogen on basic secretagogue-induced 
histamine release from RPMCs. RPMCs from female SD rats were pre-incubated with 
BSA-conjugated estradiol (BSA-E2) for 10 minutes before challenge with compound 
48/80. Compound 48/80 induced histamine release from BSA-E2 treated (•) and 
untreated (*) RPMCs are shown. Results are given as the means 士 SEM for n : 3. 
Asterisks indicate statistically significant (p<0.05 at least) different levels of histamine 
release when compared to that induced by compound 48/80 alone. 
174 
� 
Chapter 4: Elucidating the Mechanism Underlying the Effects of Oestrogens 
On Rat Peritoneal Mast Cells 
100-1 
Male 
7 80- Female 
s r 60-
o 
和 5 40- J 
I « • ••垂 J ® » m ^ ^ ^ ^ ^ 
- 2 0 - F F ^ I ^ ^ 
oJ 
I 1 1 1 1 1 -11 -9 -7 -5 
[BSA-Estradiol] (log M) 
Figure 4.39 Percentage inhibition of compound 48/80 induced histamine release from 
RPMCs. Compound 48/80 induced inhibitory percentage of histamine release from male 
RPMCs and female RPMCs by BSA-conjugated estradiol were compared. Results are 
given as the means 士 SEM for n = 3. 
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Figure 4.40 Effect of oestrogen on neuropeptide-induced histamine release from RPMCs. 
RPMCs from male SD rats were pre-incubated with 17/3-estradiol for 10 minutes before 
challenge with substance P. Substance P induced histamine release from 17/5-estradiol 
treated ( • ) and untreated (*) RPMCs are shown. Results are given as the means 士 SEM 
for n = 4. Asterisks indicate statistically significant (p<0.05 at least) different levels of 
histamine release when compared to that induced by substance P alone. 
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Figure 4.41 Effect of oestrogen on neuropeptide-induced histamine release from RPMCs. 
RPMCs from female SD rats were pre-incubated with 17/3-estradiol for 10 minutes 
before challenge with substance P. Substance P induced histamine release from 17/3-
estradiol treated ( • ) and untreated (*) RPMCs are shown. Results are given as the means 
士 SEM for n = 4. Asterisks indicate statistically significant (p<0.05 at least) different 
levels of histamine release when compared to that induced by substance P alone. 
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Figure 4.42 Percentage inhibition of substance P induced histamine release from RPMCs. 
Inhibitory percentage of substance P induced histamine release from male RPMCs and 
female RPMCs by 17j(3-estradiol were compared. Results are given as the means 士 SEM 
for n 二 4-5. There is no significant different between sexes. 
178 
� 
Chapter 4: Elucidating the Mechanism Underlying the Effects of Oestrogens 
On Rat Peritoneal Mast Cells 
17p-estradiol + sub P ( S H A M ) 
• 17p-estradiol + sub P (〇VX) 
• substance P alone ( S H A M ) 
• substance P alone (〇VX) 
g 4 � i 
I T 
"35 4 
20- + + - 二 
S 10- * * 
^ oJ 
• • • • • • -11 -9 -7 -5 
[17p-estradiol] (log M) 
Figure 4.43 Effect of oestrogen on neuropeptide-induced histamine release from RPMCs. 
RPMCs from sham-operated and ovariectomized female SD rats were pre-incubated 
with 17i3-estradiol for 10 minutes before challenge with substance P. Results are given 
as the means 士 SEM for n = 3. Asterisks indicate statistically significant (p<0.05 at least) 
different levels of histamine release when compared to that induced by substance P 
alone. 
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Figure 4.44 Percentage inhibition of substance P induced histamine release from RPMCs. 
Inhibitory percentage of substance P induced histamine release by 17|S-estradiol from 
sham-operated RPMCs and ovariectomized RPMCs were compared. Results are given 
as the means 士 SEM for n = 3.There is no significant difference between operated rats. 
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Figure 4.45 Effect of selective oestrogen receptor modulator on neuropeptide-indueed 
histamine release from RPMCs. RPMCs from male SD rats were pre-incubated with 
tamoxifen for 10 minutes before challenge with substance P. Substance P induced 
histamine release from tamoxifen treated ( • ) and untreated {*) RPMCs are shown. 
Results are given as the means 士 SEM for n = 4. Asterisks indicate statistically 
significant (p<0.05 at least) different levels of histamine release when compared to that 
induced by substance P alone. 
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Figure 4.46 Effect of selective oestrogen receptor modulator on neuropeptide-induced 
histamine release from RPMCs. RPMCs from female SD rats were pre-incubated with 
tamoxifen for 10 minutes before challenge with substance P. Substance P induced 
histamine release from tamoxifen treated ( • ) and untreated (*) RPMCs are shown. 
Results are given as the means 士 SEM for n = 3. Asterisks indicate statistically 
significant (p<0.05 at least) different levels of histamine release when compared to that 
induced by substance P alone. 
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Figure 4.47 Percentage inhibition of substance P induced histamine release from RPMCs. 
Inhibitory percentage of substance P induced histamine release from male RPMCs and 
female RPMCs by tamoxifen were compared. Results are given as the means 士 SEM for 
n = 3-4. There is no significant difference between sexes. 
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Figure 4.48 Effect of selective oestrogen receptor modulator on neuropeptide-induced 
histamine release from RPMCs. RPMCs from male SD rats were pre-incubated with 
raloxifene for 10 minutes before challenge with substance P. Substance P induced 
histamine release from raloxifene treated ( • ) and untreated (*) RPMCs are shown. 
Results are given as the means 士 SEM for n = 4. Asterisks indicate statistically 
significant (p<0.05 at least) different levels of histamine release when compared to that 
induced by substance P alone. 
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Figure 4.49 Effect of selective oestrogen receptor modulator on neuropeptide-induced 
histamine release from RPMCs. RPMCs from female SD rats were pre-incubated with 
raloxifene for 10 minutes before challenge with substance P. Substance P induced 
histamine release from raloxifene treated ( • ) and untreated (*) RPMCs are shown. 
Results are given as the means 士 SEM for n = 4. Asterisks indicate statistically 
significant (p<0.05 at least) different levels of histamine release when compared to that 
induced by substance P alone. 
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Figure 4.50 Percentage inhibition of substance P induced histamine release from RPMCs. 
Inhibitory percentage of substance P induced histamine release from male RPMCs and 
female RPMCs by raloxifene were compared. Results are given as the means 士 SEM for 
n = 4. There is no significant between sexes. 
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Figure 4.51 Effect of membrane impermeable oestrogen on neuropeptide-induced 
histamine release from RPMCs. RPMCs from male SD rats were pre-incubated with 
BSA-conjugated estradiol (BSA-E2) for 10 minutes before challenge with substance P 
(sub P). Substance P induced histamine release from BSA-E2 treated ( • ) and untreated 
(*) RPMCs are shown. Results are given as the means 士 SEM for n = 4. Asterisks 
indicate statistically significant (p<0.05 at least) different levels of histamine release 
when compared to that induced by substance P alone. 
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Figure 4.52 Effect of membrane impermeable oestrogen on neuropeptide-induced 
histamine release from RPMCs. RPMCs from female SD rats were pre-incubated with 
BSA-conjugated estradiol (BSA-E2) for 10 minutes before challenge with substance P 
(sub P). Substance P induced histamine release from BSA-E2 treated ( • ) and untreated 
(*) RPMCs are shown. Results are given as the means 士 SEM for n = 3. Asterisks 
indicate statistically significant (p<0.05 at least) different levels of histamine release 
when compared to that induced by substance P alone. 
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Figure 4.53 Percentage inhibition of substance P induced histamine release from RPMCs. 
Inhibitory percentage of substance P induced histamine release from male RPMCs and 
female RPMCs by BSA-conjugated estradiol were compared. Results are given as the 
means 士 SEM for n = 3—4. 
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Figure 4.54 Compared values of different oestrogen receptor agonists and SERMs on 
inhibition of basic secretagogue, compound 48/80，induced histamine release from male 
RPMCs. Results are given as the means 士 SEM for n = 3 - 5. 
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Figure 4.55 Compared values of different oestrogen receptor agonists and SERMs on 
inhibition of basic secretagogue, compound 48/80, induced histamine release from 
female RPMCs. Results are given as the means 士 SEM for n = 3 — 4. 
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Figure 4.56 Compared values of different oestrogen receptor agonists and SERMs on 
inhibition of neuropeptide, substance P, induced histamine release from male RPMCs. 
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Figure 4.57 Compared values of different oestrogen receptor agonists and SERMs on 
inhibition of neuropeptide, substance P, induced histamine release from female RPMCs. 
Results are given as the means 士 SEM for n = 3 - 4. 
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